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ABSTRACT 
L-serine, a non-essential amino acid, plays a role in the biosynthesis of the amino acids, 
proteins, purine and pyrimidine nucleotides.  It is important for the proper functioning of 
the nervous system.  It has been considered in the treatment of patients with schizophrenia, 
depression, chronic fatigue syndrome and psychomotor retardation, and of the seizures 
encountered in patients with rare inborn errors of L-serine biosynthesis.  However, there are 
no reports in the literature of the direct cardiovascular effects of L-serine.  Using 
normotensive Sprague-Dawley rats, Sprague-Dawley rats rendered hypertensive by chronic 
treatment with the nitric oxide (NO) synthase inhibitior NG nitro L-arginine methyl ester 
(L-NAME) and spontaneously hypertensive rats (SHR), the present study examined the in 
vitro and in vivo effects of L-serine.  In vitro studies focused on L-serine induced changes 
in phenylephrine constricted third order branches of rat mesenteric arterioles while the in 
vivo studies examined the effects of intravenous infusion of L-serine on mean arterial 
pressure (MAP) and heart rate (HR) in intact anaesthetized rats.  L-serine (10 to 200 
µmol/L) evoked concentration-dependent vasodilatation in phenylephrine constricted 
endothelium-intact, but not in endothelium-denuded, rat mesenteric arterioles.  The 
vasodilator responses to L-serine were absent in the combined presence of apamin, a 
calcium activated small conductance potassium  (SKCa) channel inhibitor, and TRAM-34, a 
calcium activated intermediate conductance potassium (IKCa) channel inhibitor, or ouabain, 
a sodium pump inhibitor and barium (Ba2+), an inward rectifying potassium (Kir) channel 
inhibitor, or when the vessels were depolarized by potassium chloride.  The maximal 
vasodilatation response (Emax) to L-serine was higher in vessels from L-NAME treated rats 
(40%) than from control rats (20%).  In anesthetized rats, L-serine evoked a rapid, 
reversible, dose-dependent fall in MAP (without a significant change in HR), which was 
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more pronounced in L-NAME treated rats (> 60 mmHg) than in normotensive control rats 
(25 mmHg).  The fall in MAP was inhibited (p<0.01) by apamin plus charybdotoxin 
pretreatment.  Charybdotoxin was used in place of Tram-34 in in vivo studies since Tram-
34 is not soluble in water or saline.  In age matched Sprague-Dawley, Wistar-Kyoto 
(WKY) and SHR strains, D-serine had the same effects on MAP and HR as L-serine; 
however, L-serine evoked a greater maximal fall in MAP in all strains, and the effect was 
more pronounced in hypertensive rats.  In contrast, the infusion of glycine, a metabolite of 
L-serine led to a dose-dependent fall in MAP in normotensive rats but a dose-dependent 
increase in MAP in both SHR and L-NAME treated hypertensive WKY rats.  Both the 
depressor and pressor responses to glycine were abolished by pretreatment with the N-
methyl D-aspartate receptor antagonist, MK-801.  Regional hemodynamic studies 
performed using the fluorescent tagged microsphere distribution technique revealed that the 
fall in MAP and  profound decrease in total peripheral resistance (TPR) evoked by acute L-
serine infusion is due to increased blood flow in the splanchnic region and more 
particularly in the small intestinal vascular beds.  This effect is blocked by the combined 
treatment with the KCa channel inhibitors, apamin plus charybdotoxin.  Although resting 
MAP and TPR are higher, and cardiac output (CO) is lower both in SHR and in WKY rats 
rendered hypertensive by L-NAME treatment compared to normotensive WKY rats, L-
serine infusion leads to a rapid fall in TPR and MAP, and an increase in CO in all models.  
This effect was more profound in the hypertensive rats.  These findings suggest that L-
serine could be helpful in overcoming splanchnic organ failure observed in patients with 
cardiopulmonary bypass.  In addition, L-serine, either alone or in combination with other 
antihypertensive medications, could be considered in the management of endothelial 
dysfunctional states with reduced NO bioavailability such as hypertension and diabetes. 
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CHAPTER 1  
INTRODUCTION 
 
1.1. Hypertension: An Overview 
 “Hypertension” is the medical term for blood pressure (BP) that remains high over 
time.  High blood pressure is a very common disorder in which the pressure in the arteries 
is too high especially in middle-aged and elderly people.  Once it has developed, it tends to 
last for life.  High BP puts strain on the heart and the circulatory system, which can 
ultimately cause damage to several organs leading to heart failure, stroke and renal failure.  
As per medical guidelines, a BP reading of 120/80 (systolic/diastolic) millimeter of 
mercury (mmHg) is considered to be normal.  Pre-hypertension is a condition where BP is 
elevated above normal but not to the level considered to be high BP.  The latest 
classification of BP values proposed by the joint national committee (JNC 7) of the 
National Institutes of Health, USA, is given in the table below (Table 1).  According to the 
JNC-7 classification a BP value of 140/90 mmHg or higher is considered as high blood 
pressure (Chobanian et al., 2003).  High blood pressure is a 'risk factor' for developing 
cardiovascular diseases such as myocardial infarction, stroke, renal failure, transient 
ischemic attacks and peripheral vascular diseases (Lawes et al., 2008).  Hypertension is the 
most common cardiovascular disease and is a major public health problem in both 
developed and developing countries (Kearney et al., 2005; Lawes et al., 2003).  It produces 
a marked effect on patients, relatives and society, either because of hypertension per se or 
through its complications which can produce premature death or permanent disability.   
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Table 1. JNC-7 Classification of blood pressure for adults 
BP 
Classification 
SBP* 
mmHg 
DBP* 
mmHg 
Normal <120 and <80 
Prehypertension 120-139 or 80-89 
Stage 1 
Hypertension 
140-159 or 90-99 
Stage 2 
Hypertension 
>/=160 or >/=100 
 *DBP, diastolic blood pressure; *SBP, systolic blood pressure. 
The risk of developing a cardiovascular complication is higher when the individual has 
hypertension combined with other risk factors such as diabetes, atherosclerosis, 
hyperlipidemia and insulin resistance state (Longo-Mbenza et al., 2002).  Epidemiological 
studies show that there are significant geographical differences in the occurrence of 
hypertension and its complications both between and within countries.  This geographical 
variation is considered to be influenced by the interaction of nutritional and environmental 
factors with the subject's genetic predisposition and susceptibility to develop hypertension.  
It is known that in people with hypertension more than 90 to 95 % have essential or 
idiopathic hypertension with unknown etiology.  Only a small percentage of the 
hypertensive patients have an identifiable cause for secondary hypertension.  Treating 
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hypertension involves lifestyle changes and pharmacotherapy with appropriate 
antihypertensive agents (Chobanian et al., 2003; Chockalingam et al., 2008). 
 
1.1.1. Blood Pressure Regulatory Mechanisms 
 BP in the body is regulated at multiple levels through complicated interacting 
networks.  These regulatory systems can be divided into extrinsic mechanisms and intrinsic 
mechanisms. 
 
1.1.1.1. Extrinsic Mechanisms 
 The extrinsic control systems include the sympathetic nervous system (SNS), 
parasympathetic nervous system (PNS), and the circulating hormones which contribute to 
the regulation of BP and blood volume.  
 
1.1.1.1.1. Nervous System 
 The nervous system plays an important role in the regulation of blood volume and 
BP.  The BP regulatory center in the medulla plays a central role in regulation.  Blood 
vessels are primarily innervated with sympathetic nerve fibers while the heart receives both 
sympathetic and parasympathetic innervations (Reis et al., 1984).  Activation of the SNS 
leads to an increase in the vascular smooth muscle (VSM) tone resulting in vasoconstriction 
of the both resistance and capacitance vessels.  This leads to an increase in total peripheral 
resistance (TPR).  SNS activation also increases the heart rate (HR) and force of 
contraction, and causes renin release.  Activation of the SNS also causes an increase in the 
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pre/post capillary resistance ratio, which leads to a decrease in capillary pressure and 
reabsorption of tissue fluid (Brunton LL, Parker KL, Lazo SJ. 2005.  Goodman and 
Gillman's The Pharmacological Basis of Therapeutics. 11th Edition).  
 
1.1.1.1.2. Humoral Systems 
 The humoral system regulates BP mainly through the renin angiotensin aldosterone 
system (RAAS), and other mediators described below. 
 
1.1.1.1.2.1. Renin Angiotensin Aldosterone System 
 RAAS is a major endocrine system that contributes to the regulation of body fluid 
and BP.  Decrease in perfusion of the juxtaglomerular apparatus in the kidney due to low 
BP results in the release of renin (Weber et al., 1975).  Renin cleaves an inactive peptide 
angiotensinogen (alpha 2 globulin circulating in the blood), which promotes the formation 
angiotensin I (Ang I).  Ang I is converted to angiotensin II (Ang II) by an enzyme found in 
lung capillaries called angiotensin-converting-enzyme (ACE).  Ang II is a potent 
vasoconstrictor.  Ang II acts as an agonist in an endocrine, paracrine, autocrine and 
intracrine fashion (Paul et al., 2006).  Ang II stimulates the secretion of aldosterone from 
the adrenal cortex.  Aldosterone causes the kidney tubules to retain sodium and water.  This 
increases the blood volume which contributes to an increase in BP.  RAAS hormonal 
system responds to low blood volume or a fall in BP (Solmon et al., 2005).   
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1.1.1.1.2.2. Arginine Vasopressin System 
 Arginine vasopressin (AVP) is a decapeptide which is also called antidiuretic 
hormone (ADH).  AVP is derived from a prehormone which is synthesized in 
hypothalamus and stored in the posterior pituitary gland (Vander et al., 1995; Caldwell et 
al., 2006).  AVP plays a major role in the reabsorption of water from the collecting ducts in 
the kidney via activation of V2 receptors while at pharmacological doses it exerts a 
profound vasoconstriction by activating V1 receptors found on vascular smooth muscle 
cells (VSMC) (McNeill, 1983; Gopalakrishnan et al., 1991).  
 
1.1.1.1.2.3. Atrial Natriuretic Peptide 
 Atrial natriuretic peptide (ANP) is produced and released by cardiomyocytes of the 
atria of the heart.  It is released in response to atrial stretch, stretching of the vessel walls, 
stimulation of beta receptors, hypervolemia, hypernatremia, elevation in Ang II and 
following exercise.  It exerts both, a natriuretic and a vasodilatory effect.  The overall effect 
of ANP is to counter RAAS mediated increase in BP (de Bold, 1985). 
 
1.1.1.1.2.4. Oubain like Factor 
 An endogenous substance, an oubain like factor (OLF) that is indistinguishable 
from the digitalis glycoside, oubain, has been found circulating in blood (Hamlyn et al., 
1991).  This substance inhibits Na+/K+ activated ATPase and induces natriuresis and 
vasoconstriction. OLF is released in response to high sodium intake, hypervolemia and in 
conditions of cardiovascular disease state such as hypertension (Goto et. al., 1998). 
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1.1.1.2. Intrinsic Mechanisms 
 The intrinsic system regulates blood flow mainly within the tissue/organ or remains 
restricted to specific regional vascular beds.  This mechanism includes myogenic 
mechanism which refers to the property of the muscle tissue to respond to stretch.  It is 
likely that metabolic and humoral mechanisms contribute to the regulation of blood flow as 
an intrinsic control system (Shepherd et al., 1979; 1981 and Monos et al., 1995).  In 
addition to the extrinsic and the intrinsic regulatory mechanisms, the endothelium is now 
widely recognized as a one of the major regulators of BP and blood flow.  The endothelium 
can be considered as an endocrine organ in its own right and can be considered as a part of 
the humoral systems of regulation or as a separate system.  It releases many vasodilatory 
and vasoconstrictor mediators and will be described in detail below. 
 
1.1.1.2.1. Endothelium 
 The endothelium is the thin layer of cells that is present as an inner lining of the 
blood vessels.  Thus, the endothelium is an interface between the lumen and the rest of the 
vessel wall.  These cells are present in the circulatory system, beginning from the heart to 
the smallest capillaries.  Endothelial cells (EC) are specialized epithelium called simple 
squamous epithelium.  EC are very important for the regulation of various functions such as 
vasodilatation, vasoconstriction, thrombosis, fibrinolysis, angiogenesis, inflammation and 
edema formation.  All of these factors contribute to the overall BP regulation by the 
endothelium.  Transit of white blood cells into and out of the blood is controlled by the EC.  
In the brain capillaries the EC have tight junctions between them as a part of the blood 
brain barrier as a protective mechanism for the brain from blood borne substances.  In the 
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renal glomerular capillaries the EC have gaps between them that allow the filtering function 
of the kidneys for urine formation.  The endothelium releases a number of vasodilatory, 
vasoconstrictive and vasoactive mediators that play a role in the cardiovascular regulatory 
functions of endothelium.  Thus, the endothelium plays an important role in the regulation 
of vascular tone (Dzau et. al., 1989).  These endothelial mediators have been listed in the 
table below followed by a description of some of the more pertinent mediators (Table 2).  
 
Table 2. Some of the most pertinent endothelial mediators and their function. 
 
Mediator Function 
Nitric oxide (NO) Vasodilator, inhibits platelet adhesion and 
aggregation 
Prostacyclin (PGI2) Vasodilator, inhibits platelet adhesion and 
aggregation 
Endothelium-derived hyperpolarizing 
factor (EDHF) 
Vasodilator 
Adenosine Vasodilator 
Atrial natriuretic peptide (ANP) Vasodilator 
Endothelin Vasoconstrictor 
 
Moreover, other blood borne mediators and mediators released from nerves act on the 
endothelium, platelets and vascular smooth muscle to regulate vascular tone, platelet 
function, capillary permeability and other cardiovascular functions.  These mediators 
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include angiotensin II (Ang II), norepineprine, histamine, bradykinin, 5-hydroxytryptamine 
(5-HT) and thromboxane.  In a physiological state there is a balance between these 
vasoconstrictor and vasodilator agents.  In disease states such as hypertension and diabetes, 
this balance is disturbed due to altered bioavailability of one or more of the endothelial 
mediators such as NO (Levy et al., 1997).   
   
1.1.1.2.2. Endothelium Derived Vasodilator Mediators  
 The endothelium produces a number of vasodilatory mediators such as EDHF, PGI2 
and NO (Moncada et al., 1979; Furchgott et al., 1980; Brandes et al., 2000).  Carbon 
monoxide (Maines et al., 1997; Christian et al., 1999) and hydrogen sulfide (H2S) (Yang G 
et al., 2008) have also been added to the list of vasodilatory mediators released from the 
endothelium.  
 
1.1.1.2.2.1. Nitric Oxide  
 Furchgott described an endothelium-derived relaxing factor (EDRF) in 1980 that 
causes the vessel to relax.  Endothelium-dependent agonists such as acetylcholine (ACh) 
and bradykinin stimulate EDRF production.  EDRF was identified as NO in 1987 (Palmer 
et al., 1987; Ignarro et al., 1987).  A lot of research has been done since in the role of NO in 
the cardiovascular and other body systems and functions.  NO plays a pivotal role in the 
regulation of vascular tone and homeostasis (Ignarro et al., 1987; Palmer et al., 1987; Vane 
et al., 1990).  eNOS knockout mice develop hypertension (Shesely et al., 1996).  NO is 
synthesized from L-arginine by nitric oxide synthase (NOS) (Palmer et al, 1988).  There are 
three isoforms of the NOS enzyme: neuronal (nNOSor type I NOS), inducible (iNOS or 
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type 2 NOS) and endothelial (eNOS or type 3 NOS) (Moncada et al., 1991).  Each of the 
isoforms has separate locations.  nNOS and eNOS are calcium-dependent and produce low 
levels of NO as a cell signaling molecule.  iNOS is calcium-independent and produces large 
amounts of NO which can be cytotoxic or bactericidal (Bernardeau et al., 2001).  NOS 
oxidizes the guanidino group of L-arginine in a process that consumes five electrons and 
results in the formation of NO with stoichiometric formation of L-citrulline.  The process 
involves the oxidation of NADPH and the reduction of molecular oxygen.  The 
transformation occurs at a catalytic site adjacent to a specific binding site of L-arginine.  
Tetrahydrobiopterin is required as a co-factor.  The target of NO in the vascular smooth 
muscle cell is soluble guanylate cyclase.  Stimulation of suoluble guanylate cyclase (sGC) 
causes an increase in cyclic guanosine monophosphate (cGMP) which ultimately leads to 
smooth muscle relaxation.  NO directly causes hyperpolarization and relaxation of VSMC 
by activating calcium-dependent potassium channels which is independent of cGMP 
pathway (Bolotina et al., 1994).  NO is an important regulator and mediator of numerous 
processes in the cardiovascular system, nervous system and the immune system.  Thus, NO 
causes smooth muscle relaxation resulting in dilatation of the blood vessel and an increase 
in the blood flow.  In the nervous system NO is involved in neurotransmission and has been 
associated with functions such as memory formation and avoidance learning.  In the 
immune system production of large amounts of NO from iNOS acts as a bactericidal and 
cytotoxic agent against tumor cells.  Acetylcholine (ACh), cytokines, platelet derived 
factors stimulate NO production by eNOS (Yuan, 2006).  The vasodilator action of NO 
controls renal extracellular fluid homeostasis which is essential for the regulation of blood 
flow and BP (Yoon et al., 2000).  Role of endogenous and exogenous NO on renin 
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secretion are mediated by a cGMP-induced inhibition of cAMP degradation and more 
exclusively mediated by phosphodiesterase (PDE)-3 (Kurtz et al., 1998).  
 
1.1.1.2.2.2. Prostacyclin   
 Prostacyclin (PGI2) is a prostanoid.  Prostanoids are biologically active lipids, 
derived from twenty-carbon essential fatty acids (eicosanoids).  They are further subdivided 
into three main groups, prostaglandins, PGI2 and thromboxane (TXA2), each one of them 
having distinct functions (Tohgi et al., 1992).  PGI2 is produced in the EC from cell 
membrane arachidonic acid.  The enzyme prostacyclin synthase catabolizes the 
intermediate metabolite prostaglandin H2 into PGI2.  PGI2 a vasodilator and it inhibits 
platelet aggregation and VSMC proliferation. PGI2 binds to G protein coupled receptor 
which activates adenylyl cyclase to produce cyclic 3’, 5’ adenosine monophosphate 
(cAMP).  cAMP binds to specific locations on the regulatory units of the protein kinase, 
and causes dissociation between the regulatory and catalytic subunits, thus activating the 
catalytic units and enabling them to phosphorylate substrate proteins (Hanoune et al., 
2001).  cAMP activates protein kinase A (PKA). Activation of PKA phosphorylates 
number of proteins which inhibits myosin light-chain kinase and leads to smooth muscle 
relaxation.  Increase in cAMP inhibits platelet activation and opposes increase in cytosolic 
free calcium levels in VSMC and promotes vasodilatation (Moncada et al., 1979).  PGI2 
contributes substantially to myocardial protection (Utsunomiya et al., 1982; Csanyi et al., 
2006).  
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1.1.1.2.2.3. Endothelium Derived Hyperpolarizing Factor  
 Endothelium derived hyperpolarizing factor (EDHF) is proposed to be a 
vasodilatory mediator whose identity is controversial.  EDHF is released by EC and leads 
to NO/PGI2 independent vasodilatation by relaxation of adjacent VSMC (Garland et al., 
1996).  The mechanism and nature of EDHF action is different among species, strain and 
between vascular beds (Mcguire et al., 2001).  Several researchers have proposed that K+ is 
the EDHF (Dong et al., 1997; McCulloch et al., 1997; Edwards et al., 1998).  
Epoxyeicosatrienoic acid (EET), a cytochrome P450 (CYP)-derived metabolite of 
arachidonic acid, produced a NO/PGI2-independent relaxation in guinea-pig carotid artery 
which is pharmacologically distinct from the EDHF mediated response in rat mesenteric 
artery (Fleming et al., 2000; Mcguire et al., 2001).  Hydrogen peroxide (H2O2) was 
proposed to be an EDHF in mouse, human mesenteric and porcine coronary arteries 
(Matoba et al., 2000; 2002; and 2003).  C-natriuretic peptide (CNP) also has been proposed 
to act as an EDHF (Chauhan et al., 2003).  L-NAME-insensitive NO was suggested to act 
as an EDHF in rabbit carotid artery and in rat small resistance arteries (Cohen et al., 1997; 
Chauhan et al., 2003).  Myoendothelial gap junction (MEGJ) coupling between the 
endothelium and smooth muscle, has also been implicated in EDHF activity in many 
arteries, whereas EDHF activity may simply be due to the transfer of an endothelium 
derived hyperpolarization, and not to the activity of a factor per se (Coleman et al., 2001; 
Griffith , 2004).  Thus there is no clear consensus with regard to the nature of EDHF.  
Based on experimental evidence it is agreed that there is an additional mechanism of 
vasodilatation that exists and it is NO/PGI2 independent but mediates endothelium-
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dependent hyperpolarization of both endothelium and VSMC and originates from the 
endothelium, called EDHF.  There is some agreement that shear stress or receptor 
activation plays a critical role in the release of intracellular calcium which activates 
endothelial/non-endothelial potassium channels (Mcguire et al., 2001; Griffith et al., 2004).  
This rise in intracellular free calcium activates small (SKCa) and intermediate (IKCa) 
conductance calcium-activated potassium channels which are present on EC.  This results 
in the release of an EDHF which hyperpolarizes the adjacent VSMC.  The EDHF mediated 
response was abolished in the presence of depolarizing concentrations of potassium 
(Quilley et al., 1997).  Inclusion of a combination of apamin (SKCa channel inhibitor), 
TRAM-34 (IKCa channel inhibitor), or charybdotoxin (IKCa and BKCa channel inhibitor) or 
ouabain (Na+ pump inhibitor) and Ba2+ (Kir channel inhibitor) blocked the EDHF mediated 
hyperpolarization of VSMC (Edwards et al., 1998; Parsons et al., 1994). EDHF 
compensates for the lack of NO and mediates ACh-induced vasodilation in chronic NOS-
inhibited SD rats (Desai et al., 2006). 
  
1.1.1.2.2.4. Carbon Monoxide 
Carbon monoxide also relaxes vascular smooth muscle (Marks et al., 1991).  
Carbon monoxide is produced by the microsomal heme oxygenases (HO).  HO catabolizes 
heme molecules into biliverdin, ferrous iron and carbon monoxide.  There are three 
isoforms of HO.  HO-1 is inducible, HO-2 and HO-3 are constitutive.  HO-1 is a stress 
protein (also known as heat-shock protein HSP32) and it acts as a general cytoprotectant 
against increased stress such as a bacterial infection or an arthritic joint where the 
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expression and activity of HO increases along with an increase in carbon monoxide levels.  
Heme comes from the breakdown of hemoglobin, myoglobin and other heme containing 
proteins.  The target of carbon monoxide is sGC causing an increase in cGMP.  HO-3 is 
considered to be a sensor of oxygen (Maines et al., 1997; Christian et al., 1999).  
 
1.1.1.2.2.5. Hydrogen sulfide 
H2S has been shown to play a role as a vasorelaxant and regulator of blood pressure 
in mice.  Knockout mice lacking the enzyme cystathionine γ-lyase (CSE) have higher blood 
pressure (Yang et al., 2008).  H2S is synthesized from L-cysteine by cystathionine ß-
synthase (CBS) and CSE.  CSE is the main H2S forming enzyme in the cardiovascular 
system whereas CBS is the main enzyme in the central nervous system (Wang et al., 2002).  
H2S causes vasorelaxation by activating KATP channels in the vascular smooth muscle and 
causing hyperpolarization (Wang et al., 2002). 
 
1.1.1.2.3. Endothelium Derived and Other Vasoconstrictor Factors  
 In normal physiological condition, the release of NO is predominant.  NO 
modulates the release and resultant effect of vasoconstricting factors (Busse et al., 1985).  
In pathological conditions such as hypertension, atherosclerosis and diabetes, NO 
bioavailability and its vasodilator effect becomes impaired due to endothelial dysfunction, 
resulting in an imbalance between the endothelium derived relaxing and contracting factors.  
In such disease states, impairment of the release of NO augments the effects and release of 
endothelium derived vasoconstrictor factors, resulting in widespread vasoconstriction and 
an increase in BP (Vanhoutte et al., 1986).  
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1.1.1.2.3.1. Endothelin  
 ET is a 21 amino acid vasoconstrictor peptide and it is produced primarily in the 
endothelium (Yanagisawa et al., 1988).  ET is one of the most potent vasoconstrictors and it 
is implicated in several vascular diseases.  ET has three isoforms, namely ET-1, ET-2 and 
ET-3 and two receptors namely ETA and ETB (Hynynen et al., 2006).  ET1 released from 
the endothelium exerts vasoconstriction via activation of ETA receptors present on adjacent 
VSMC (Schinelli et al., 2006).  The ETB subtype is predominantly expressed on EC and 
ETB receptor activation on EC results in increased NO generation (Batra et al., 1993; 
Hopfner et al., 1999).  In addition, in certain vascular beds, there are ETB receptors present 
on VSMC which in concert with ETA promote vasoconstriction (Batra et al., 1993; Hopfner 
et al., 1999).  ET is rapidly metabolized when it passes through the lungs.  Interaction of 
ET1 with its ETB receptors leads to its internalization and rapid breakdown in the lungs 
(Sokolovsky, 1995).  With the exception of ET, all vasoactive substances have short half-
lives and are involved in short term regulation of vascular tone (Yanagisawa et al., 1988; 
Agapitov et al., 2002).  Both ETA and ETB receptors are G-protein coupled receptors that 
are linked to phospholipase C (PLC) mediated Ca2+ mobilization and protein kinase C 
(PKC) activation.  ET1 is a powerful long lasting vasoconstrictor agonist because it can 
promote Ca2+ independent effects subsequent to its effect mediated via activation of PKC 
and Rho-kinase (Christopher et al., 2003).  Recently it has been suggested that both ETA 
and ETB receptors are found in the nervous system and play a critical role in 
neurotransmission.  ET plays an important role in vascular function (Bernes et al., 1997).   
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1.1.1.2.3.2. Vasoconstrictor Prostanoids  
 TXA2 in another prostanoid synthesized in platelets by thromboxane A synthase 
from endoperoxides produced by cyclooxygenase (COX) enzyme from arachidonic acid 
(Tohgi et al., 1992).  PGI2 and TXA2 have important and opposing functions for the 
maintenance of physiological vascular tone.  An optimum balance is maintained between 
PGI2 and TXA2 production in healthy states.  TXA2 binds to thromboxane receptors (G-
protein coupled receptors coupled to the G protein Gq) and promotes platelet aggregation, 
vasoconstriction, and smooth muscle proliferation.  TXA2 and PGI2 are therefore important 
mediators of pathological vascular events including thrombosis and atherogenesis.  
 
1.1.1.2.3.3. Free Radicals  
 Free radicals are molecules or ions with unpaired electrons on an otherwise open 
shell configuration.  These unpaired electrons are usually highly reactive.  Free radicals 
include oxygen derived free radicals, which are commonly known as reactive oxygen 
species (ROS) (Halliwell, 1991).  ROS include superoxide anions (O2•-), hydroxyl radicals 
(·OH), as well as highly reactive non-radicals which do not have an unpaired electron in 
their orbit, such as hydrogen peroxide (H2O2) (Halliwell, 1991).    Free radicals and ROS 
react with proteins, lipids and DNA to alter their structure and function.  Oxidative stress is 
caused when there is an excess of free radicals and ROS production causing an imbalance 
with antioxidant defenses such as antioxidant enzymes.  These free radicals are responsible 
for aging, tissue damage, and diseases.  Superoxide anion can react with NO to form 
peroxynitrite (Gryglewski et al., 1986).  Superoxide anion also stimulates the production of 
TXA2 via activation of prostaglandin H synthase (de Artinano et al., 1999).  In 
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cardiovascular disease state there is oxidative stress with a resultant increase in free radical 
generation.  This in turn decreases superoxide dismutase (SOD) activity, vitamin E and NO 
production (Vijay et al., 1993).  SODs are a class of enzymes that catalyzes the dismutation 
of superoxide to oxygen and hydrogen peroxide (McCord et al., 1969; McCord et al., 
2005).  They serve as an important antioxidant.  SODs have three isoforms and they are 
found in different cell compartments. SOD-1 is found in the cytoplasm, SOD-2 in 
mitochondria and SOD-3 is extracellular.  This excessive increase in free radical generation 
can inactivate PGI2 synthase and decrease the expression of eNOS (Vidal et al., 1998; 
Davidge et al., 2001).  It has been suggested that free radicals contribute to 
vasoconstriction, and free radical scavengers such as tempol successfully restore the 
generation of PGI2 and NO, thereby augmenting vasodilatation (Katusic et al., 1989). 
 
1.1.1.2.4. Endothelial dysfunction   
Endothelial dysfunction is a hall mark of cardiovascular diseases such as 
hypertension (Virdis et al., 2008) and diabetes and it is often an early finding in these 
conditions (Ulvi, 2005).  Grossly speaking endothelial dysfunction can be defined as the 
dysfunction of one of more aspects of the regulatory function of the endothelium.  Thus, 
vasodilation, vasoconstriction, coagulation/anticoagulation, fibrinolysis, angiogenesis etc 
may be affected by endothelial dysfunction (Le Brocq et al., 2008).  However, endothelial 
dysfunction is more commonly measured as the ability of the blood vessel to relax in 
response to stimulation by endothelium-dependent agonists such as acetylcholine or 
bradykinin. Thus, endothelial dysfunction is commonly referred to as a reduced 
endothelium-dependent relaxation of the vessel, commonly an artery.  NO is one of the 
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main vasodilatory mediators released by the endothelium in different vascular beds and 
reduced NO bioavailability is one of the main findings in endothelial dysfunction (Schulz et 
al., 2008; Davis et al., 1997).  Patients with essential hypertension have reduced NO 
production compared to normal individuals (Forte et al., 1997).  Supplementation with 
exogenous NO, novel NO donors or NO releasing compounds have been suggested to be 
beneficial for normalizing normal biological functions in disease states with reduced NO 
production (Hou et al., 1999).  However, a more common reason for reduced NO 
bioavailability is an increase in oxidative stress with an excess of superoxide anion 
production that reacts with NO to form peroxynitrite (Darley-Usmar et al., 1995; Schulz et 
al., 2008; Pacher et al., 2007).  Endothelial dysfunction and increase in vascular resistance 
in hypertensive patients is related to the imbalance of vasodilators (NO and PGI2) and 
vasoconstrictors ET and TXA2 and TXA2 mediated vascular responses are exaggerated 
(Abe et al., 1995).  In patients with pulmonary and essential hypertension, synthesis of 
endogenous PGI2 was found to be reduced.  Exogenous infusion of PGI2 improved systemic 
circulation and decreased pulmonary artery pressure (Kadowitz et al., 1978).  Often in some 
disease conditions such as end-stage renal failure, hypercholesterolemia and in some forms 
of hypertension, circulatory asymmetric dimethylargine (ADMA) level in blood is high and 
this interferes with the L-arginine stimulated NO synthesis (Moncada et al., 1991; Vallance 
et al., 1992).  ADMA is an endogenous competitive inhibitor of NOS.  In animal models, 
acute ADMA administration increases peripheral resistance and raises systemic blood 
pressure that is reversed by L-arginine.  The L-arginine: ADMA ratio may be an 
endogenous determinant of arterial tone in some forms of hypertension.  In addition, the 
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endothelium generates mediators that promote as well as inhibit vascular growth other 
besides being a source for contractile and vasodilatory mediators (Luscher et al., 1993).  
 
1.2. Animal Models of Hypertension 
 Hypertension is a multifactorial and complex disease.  It involves interactions 
between genetically determined homeostatic control mechanisms and environmental factors 
(Takahashi et al., 2004).  The ideal animal model for hypertension research should have 
human-like physiology, cardiovascular anatomy, hemodynamics, and develop human 
disease characteristics and complications.  No species or experimental model can answer all 
of these needs.  So currently various experimental animal models of hypertension are used 
for hypertension research.  The general categories of animal models of hypertension are 
divided into genetic and non genetic models.  The genetic animal models of hypertension 
include those are phenotype driven with natural variation among inbred strains e.g. SHR 
and genotype-driven with genetic based manipulation of gene expression.  The non genetic 
models are developed by renovascular surgery or injury, vasoactive intervenation, dietary 
and endocrine manipulation (Pinto et al., 1998).  The non genetic models include two 
kidneys one-clip, one kidney one-clip, partial or total nephrectomy, NOS inhibition, 
deoxycorticosterone (DOCA) salt, dahl salt-sensitive and pregnancy induced (Lerman et 
al., 2005).  Mice deficient with all or individual NOS isoforms (neuronal, inducible and 
endothelial) have been developed for metabolic and hypertension research (Yang et al., 
1999; Tsutsui et al., 2006).  Mice deficient in the CSE was developed to study 
cardiovascular effect of H2S (Yang et al., 2008).  In the present study we used two different 
animal models of hypertension; a genetic model and a chronic NOS inhibition model.  
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1.2.1. Spontaneously Hypertensive Rat (SHR) 
 SHR is an animal model genetically bred to display high BP.  SHR strain was 
developed from a group of outbred normotensive Wistar-Kyoto (WKY) rats mated with 
female rats with high BP from the same strain.  Subsequent brother and sister matings with 
continued selection for high BP from the same group led to the selection of a group of rats 
that developed high BP with increases in age (Okamoto et al., 1963).  The SHR strain 
shows a functional increase in vascular resistance and this is attributed to centrally 
mediated sympathetic hyperactivity (Falckh et al., 1992).  SHR shows structural changes in 
blood vessel wall and supersensitivity of the blood vessels to vasoconstrictor stimuli which 
is similar to humans with high BP (Bohr et al., 1984 and 1988).  Initial studies for clinical 
efficacy of angiotensin receptor antagonists (ARB) in the management of essential human 
hypertension were primarily conducted in the experimental SHR model (Timmermans et 
al., 1993).  SHR with suppressed NO synthesis very closely mimic the cardiac and renal 
outcomes seen in patients with essential hypertension.  Thus, the SHR strain is considered 
one of the most useful models in hypertension research. 
 
1.2.2. Rat Models with Chronic NOS Inhibition  
 Chronic inhibition of NO with NG-nitro-L-arginine methyl ester (L-NAME), a NOS 
inhibitor increases BP in rats (Ribeiro et al., 1992).  L-NAME induced hypertension in rats 
is characterized by changes in cardiovascular function with increases in cardiopulmonary 
reflex (Scrogin et al., 1998; Araujo et al., 1998).  Chronic L-NAME treatment up regulates 
the EDHF system in rats (Desai et al., 2006).  Chronic NO inhibition increases volume 
dependent hypertension and its pathophysiological characteristics are similar to essential 
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hypertension in humans (Lahera et al., 1992; Romeroet al., 1993).  L-NAME treated 
hypertensive rats share similar pathophysiological findings as essential hypertension in 
humans with hypertensive heart disease and end stage renal disease (Zanchi et al., 1995).  
L-NAME treated hypertensive rat models have been used in a series of studies designed to 
investigate the effects of different classes of antihypertensive agents in the prevention of 
hypertension (Nakamura et al., 2001).  Thus, the L-NAME treated hypertensive rat model 
is useful because it is foregoing, time saving and has good economic value. 
 
 
1.3. Problems in Treating Hypertension 
 Reduction of BP to the target normotensive levels in patients with hypertension is 
not easily attained.  The problem gets worse if the patients are older, obese or diabetic and 
remained untreated for a long time.  Thus, early diagnosis and appropriate treatment is 
vital.  Recently, National Health and Nutrition Examination Survey (NHANES, 2008) 
considered participants from all age groups for appropriate treatment of high BP (David et 
al, 2008).   Among all participants considered, half of the participants showed a significant 
reduction in BP to less than 140/90 mmHg, the recommended level.  Some participants did 
not show any improvement, and thus were considered as having uncontrolled hypertension, 
which may be due to poor compliance in taking the prescribed medication or having 
resistant hypertension.  People with uncontrolled or resistant hypertension normally do not 
respond to antihypertensives.  Many people with high BP need more than one medication to 
reduce their BP to the recommended level.  In addition, people may be on several other 
medications for other conditions along with antihypertensive medication which often 
interact and reduce the efficacy of the antihypertensives.  Simple reduction in BP is no 
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longer the ideal goal of hypertension treatment.  Ideally, a new agent for the treatment of 
hypertension should have the following characteristics in order to represent a significant 
advancement over the present therapy: 1) a longer duration of action, absence of 
tachycardia and orthostatic hypotension, 2) the ability to promote sodium excretion, 3) 
absence of increased plasma renin activity, 4) a mechanism of action related to the cause of 
the hypertensive disease, and 5) fewer side effects and less toxicity than seen with presently 
available agents, 6) reversal and restoration of endothelial function, structural 
cardiovascular modification induced by hypertension and reduction in platelet aggregation.  
Various approaches within the pharmaceutical industry as well as in academic research 
laboratories can be taken in search of new antihypertensive agents.  
 
1.3.1. Current Management of Hypertension 
 Treatment of hypertension involves lifestyle changes and drug therapy.  if changes 
in life style are ineffective, drug therapy is initiated, often requiring more than one agent to 
reduce BP.  All drug treatments have side effects.  There are different drug classes that can 
be used to treat high BP. 
 
1.3.2. Classification of Antihypertensive Drugs 
 Diuretics 
 1. Thiazides and related agents (hydrochlorothiazides, chlorothalidone,    
      indapamide). 
 2. Loop diuretics (furosemide, bumetanide, torsemide). 
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 3. K+ sparing diuretics (amiloride, triameterene, spiranolactone) 
 Sympatholytic Drugs 
 1. Centrally acting agents (methyldopa, clonidine, guanfacine). 
 2. Ganglionic blocking agents (trimethaphan). 
 3. Adrenergic neuron blocking agents (guanethidine, reserpine) 
 4. Beta adrenergic antagonists (propranolol, metropolol) 
 5. Alpha adrenergic antagonists (prazosin, terazosin, phentolamine,       
     phenoxybenzamine). 
 6. Mixed adrenergic antagonists (labetalol, carvedilol) 
 Vasodilators 
 1. Arterial (hydralazine, minoxidil, diazoxide) 
 2. Arterial and venous (nitroprusside) 
 Others 
 1. Ca2+ channel blockers (verapamil, diltiazem, nifedipine) 
 2. Angiotensin converting enzyme inhibitors (captopril, enalapril, lisinopril) 
 3. Angiotensin II receptor antagonists (losartan, valsartan, telmisartan) 
Diuretics are usually recommended as the first line of therapy for most people who have 
hypertension.  If one drug doesn't work, combination of antihypertensive agents often used. 
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Combination therapy is used to treat uncontrolled or resistant types of hypertension.  
Disadvantages of combination therapy are drug interactions, side effects and increased 
problems with compliance (Brunton LL, Parker KL, Lazo SJ. 2005. Goodman and 
Gillman's The Pharmacological Basis of Therapeutics. 11th Edition).  
 
1.3.3. New Promising Drugs to Treat Hypertension 
 Renin inhibitor (Aliskiren) provides comprehensive Ang II suppression by blocking 
the largest step down the RAAS pathway which is rate-limiting (Schmieder et al, 2009).   
Aliskiren was approved in 2007 by the Food and Drug Administration (FDA) to treat 
primary hypertension.  CYT006-AngQb is a vaccine designed to elicit production of  anti-
Ang II-specific antibodies has been showing promising outcomes in preclinical studies 
(Tissot et al., 2008). 
 
1.4. Beneficial Effects of Amino Acids in Hypertension  
 Amino acids play an important role as neurotransmitters and serve as precursors to 
several neurotransmitters for proper functioning of the nervous system (Munro et al., 1986).  
As early as 1972 it was first demonstrated that central administration via 
intracerebroventricular infusion of taurine, gamma-aminobutyric acid (GABA), L-alanine 
and glycine produced a hypotensive response in anaesthetized rat models (Sgaragli et al., 
1972).  Dietary supplementation of tyrosine, which is a precursor for epinephrine and 
norepinephrine has the potential to decrease BP in hypertensive animals but has minimal 
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effect in normotensive animals (Sveda et al., 1979).  Tryptophan a precursor for serotonin, 
injected intraperitoneally also has been shown to lower BP in both normotensive and 
hypertensive rats (Wolf et al., 1984).  Taurine an amino acid neurotransmitter has been 
extensively studied for its potential as an antihypertensive agent (Nara et al., 1978).  They 
concluded that supplementation of taurine in drinking water decreased BP in SHR as well 
as in stroke prone SHR.  Some studies also proposed that the BP lowering effect of taurine 
is associated with increased salt excretion and decreased sympathetic discharge (Abe et al., 
1987; Fujita et al., 1988; Militante et al., 2002; Oudit et al., 2004).  Several studies show 
that another amino acid glycine protects against oxidative stress which is encountered in 
cardiovascular disease states including hypertension (Hafidi et al., 2006).  These authors 
also proposed that glycine supplementation lowered BP probably by decreasing non-
esterified fatty acid (NEFA), triglycerides (TG) and intra-abdominal fat (IAF).  It has been 
suggested that glycine plays an important role in glutathione (GSH) synthesis.  GSH 
scavenges free radicals which can reduce the availability of NO.  Thus, GSH improves NO 
availability.  Glycine rectifies endothelial dysfunction which contributes to lowering of BP 
(Lees et al., 1996).  Glycine is thought to promote cardiovascular protection and exerts an 
antihypertensive effect via increased generation of S-nitrosoglutathione, a vasodilator 
intermediate generated from glycine which increases GSH synthesis (Lees et al., 1996).  
However, no systemic studies have been undertaken to examine the dose-dependent effects 
of glycine on BP regulation in both normotensive and hypertensive states.  The present 
study aims to address these issues.  
 
 
 24
1.5. Serine  
 Serine is an organic compound with the molecular formula HO2CCH (NH2) 
CH2OH.  It is one of the 20 naturally occurring proteinogenic amino acids.  Only the L-
stereoisomer appears to be present in proteins naturally.  Since it is synthesized in the body 
from other metabolites, it is not essential in human diet.  However, it is important for cell 
growth and viability as it is always added and included in various cell culture media.  Thus 
it is considered conditionally essential in cell culture (McCoy et al., 1956).  Silk protein is a 
rich source of L-serine and it was first obtained from silk protein in 1865 (Cramer, 1865).  
In 1902, its structure was established (Fischer et al., 1902).  In view of the presence of two 
hydroxyl groups in its structure, it was classified as a polar amino acid (Fischer et al., 
1907).  
 
1.5.1. Source of L-serine 
 L-serine is classified as a nutritionally non-essential amino acid.  The main source 
of essential amino acids is from the dietary sources, whereas non-essential amino acids are 
normally synthesized by humans and other mammals from common intermediates (Ichihara 
et al., 1957).  L-serine can be derived and biosynthesized from glucose metabolism as a 
glycolytic intermediate, 3-phosphoglycerate (3-PG), in a three-step process involving the 
enzymes: 3-phosphoglycerate dehydrogenase (3-PGDH), phosphoserine aminotransferase 
(PSAT), and phosphoserine phosphatase (PSP), dietary protein, glucose, protein 
phospholipid degradation, glycine, and threonine (Figure 1, Fischer et al., 1902; Stein et al., 
1942; Greenstein et al. 1961; de Koning et al., 2003).  L-serine synthesis and concentration 
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varies with species, tissues, and during different developmental stages (Narkewicz et al., 
1996).  The fasting plasma concentration of L-serine in a healthy human is 130 ± 30 
μmol/L (de Koning et al., 2004).  
 
Glucose 3-Phosphoglycerate Pyruvate
Phosphohydroxypyruvate
3-Phosphoserine
L-serineDietary protein Protein and phospholipiddegradation
3-PGDH
aminotransferase
PSP
Glycine
SHMT
NH3 + CO2+ 5, 10-MTHF
Glycine cleavage system
Threonine
THF
5, 10-MTHF
aldolase
 
 
Figure 1.  Various sources and biosynthetic pathways of L-serine. 
3-PGDH, 3-phosphoglycerate dehydrogenase; PSP, phosphoserine phosphatase; SHMT, 
serine hydroxyl methyltransferase; THF, tetrahydrofolate. 
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1.5.2. Pathways of L-serine Formation  
 L-serine biosynthesis involves recruitment of two major pathways, namely 
phosphorylated and non-phosphorylated forms.  The phosphorylated pathway is the 
primary pathway for L-serine synthesis involving 3-phosphoglycerate, L-phosphoserine, L-
serine and phosphohydroxypyruvate, but it has no role in gluconeogenesis since it is 
responsible for dephosphorylation of phosphoserine in many tissues and enzymes for this 
pathway are abundant in many tissues e.g. brain, testis, spleen and kidney (Snell, 1986).  
The non-phosphorylated pathway involves D-glycerate, hydroxypyruvate and L-serine. 
This pathway is confined to the liver and the kidney since enzymes for this pathway are 
restricted selectively to these organs only (Rowsell et al., 1969; Cheung et al., 1969).  
Racemic serine can be prepared from methyl acrylate (Carter et al., 1955).  The 
biosynthesis of L-serine starts with the oxidation of glycolytic intermediate, 3-
phophoglycerate to 3- phosphohydroxypyruvate and nicotinamide adenine dinucleotide 
(NAD+), which then is reduced to NADH.  Reductive amination of this ketone by 
hydrolysis gives rise to L-serine.  Serine hydroxymethyltransferase (SHMT) catalyzes the 
conversion of L-serine to glycine by retro-aldol cleavage and 5,6,7,8-tetrahydrofolate 
(THF) hydrolyzes to 5,10 methylenetetrhydrofolate (MTHF, Nelson et al., 2000).  The 
Kidney synthesizes most of the L-serine from 3-phosphoglycerate whereas the glycine 
cleavage system interacts with SHMT and their combined action gives rise to L-serine in 
fetal liver (Lowry et al., 1987).  
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1.5.3. Metabolism of L-serine 
 Metabolism of L-serine involves three major enzymes namely, L-serine dehydratase 
(SDH), serine:pyruvate/alanine:glyoxylate aminotransferase (SPT/AGT), and SHMT.  Most 
importantly, SDH and SPT/AGT participate in gluconeogenesis from L-serine (Xue et al., 
1999).  SHMT is a key enzyme that catalyzes the generation of 5,10 MTHF via formation 
of glycine from L-serine.  SHMT has two isozymes, namely cytosolic (cSHMT) and 
mitochondrial (mSHMT).  It promotes the interconversion between L-serine and glycine in 
a combined action with mitochondrial glycine cleavage system (GCS), when either amino 
acid is used or supplied (Snell, 1984).  In rodents, SDH plays the major role in comparison 
to GCS, SPT/AGT and SHMT in the metabolism of L-serine (Xue et al., 1999).  
 
1.5.4. Pathways of L-serine Utilization 
 There are various pathways of L-serine utilization (Figure 2).  L-serine plays a key 
role in the formation of myelin, lipid messenger molecules, and it is required for normal 
functioning of the central nervous system.  L-serine serves as a direct/indirect precursor for 
the synthesis of several neurotransmitters and amino acids (Mustafa et al., 2004).  
Moreover in cell growth and development, L-serine plays an essential role in the synthesis 
of purine and pyrimidine nucleotides being the source for the one carbon unit (Eagle., 1959;  
Snell et al., 1987).  
 
1.5.4.1. L-serine and Gluconeogenesis 
 Gluconeogenesis from L-serine involves two enzymes, namely SDH and SPT/AGT.  
SDH is involved in the formation of pyruvate whereas SPT/AGT is involved in the 
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formation of hydroxypyruvate from L-serine (Figure 2).  SPT/AGT enzyme distribution 
varies considerably between species (Xue et al., 1999).  In carnivores, SPT/AGT is 
distributed predominantly in the mitochondria whereas in herbivores it is present in 
peroxisomes.  In rodents, SDH is important while in humans, SPT/AGT enzyme plays a 
major role in gluconeogenesis (Xue et al., 1999).  Recently it has been suggested that in 
brain, L-serine in the presence of D-/L-serine racemase, can generate pyruvate (De Miranda 
et al., 2002).  
 
1.5.4.2. L-serine and Cystathionine Formation 
 Combined action of L-serine and homocysteine gives rise to cystathionine. 
Cystathionine is an intermediate in the synthesis of cysteine. It is generated from 
homocysteine and serine by cystathionine beta synthase, then subsequently cleaved to 
cysteine and alpha ketobutyrate by the enzymatic action of cystathionine gamma-lyase 
(Dudman et al., 1987).  L-serine is required for the synthesis of cysteine, taurine and 
sulphate (Figure 2).  Taurine and sulphate are formed in trans-sulphuration pathways. 
Taurine and sulphate are both important for the normal brain function.  Taurine is 
considered to be an inhibitory neurotrasmitter, an osmoregulator and it is also responsible 
for migration of neurons (Schousboe et al., 1992).  Deficiency of sulphate results in severe 
neurological problems since it plays an important role in the formation of steroid hormones 
and glucosphingolipids (Johnson et al., 2001).  Both cysteine and glycine are metabolic 
products of L-serine and they serve as precursors for the biosynthesis of glutathione. 
Deficiency in glutathione is responsible for the cause of hemolytic anemia and neurological 
disorders (Wullner et al., 1999).  In disease state like homocysteinuria, L-serine and glycine 
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levels are found to be low in the cerebrospinal fluid (CSF) but not in plasma; however, it is 
not clear whether in such a condition there is a decrease in the synthesis of L-serine and 
glycine or whether brain uses more L-serine and glycine (Surtees et al., 1997).  
 
1.5.4.3. L-serine and Biosynthesis of Phospholipids 
 L-serine serves as a precursor for the biosynthesis of phosphoglycerols, 
sphingolipids, sphingosine, glycolipids. Sphingolipids are myelin constituents and they are 
essential for cellular proliferation and differentiation (Perry et al., 1998).  L-serine derived 
phospholipids such as sphingosine play a central role in the production of myelin and they 
act as lipid messenger molecules (Hannun et al., 1989; Perry et al., 1998).  Ceramide is 
converted from sphingosine, which is a precursor for gangliosides and spingomyelin 
(Hannun et al., 1989).  Sphingolipids are abundant in the myelin sheath and are present in 
all membranes.  Ceramide is critical for cell survival (Hannun., 1996).  Deficiency of 
ceramide synthesis could result in apoptosis and neuronal cell death (Perry et al., 1998).  
Phosphoglycerol phosphatidylserine which is synthesized from L-serine can be converted 
to phosphatidylcholine through phophatidylethanolamine.  Phosphatidylserine plays a role 
in apoptotic cell signaling (Tyurina et al., 2000).  Impairment in phospholipid metabolism 
results in abnormalities in cerebral white matter (de Koning et al., 2000).  Thus, L-serine 
has a key role in synthesizing complex macromolecules for normal functioning of the 
central nervous system (CNS) through different signaling pathways (Figure 2).   
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Figure 2.  Involvement of L-serine in gluconeogenesis and major pathways for utilization I. 
D-/L-serine recemase, II. Serine hydroxymethyltransferase, III. Glycine cleavage system 
IV. Transmethylation of methionine, V. Trans-sulphuration of methionine, VI. Palmitoyl 
CoA.  
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1.5.4.4. Role of L-serine in the Formation of D-serine, Glycine, L-cysteine and Taurine 
 L-serine is a precursor for the neurotransmitters, D-serine, glycine and indirectly 
through L-cysteine, for the synthesis of inhibitory neurotransmitter, taurine.  D-serine 
synthesized through serine racemase from L-serine, serves as a neuromodulator and 
endogenous agonist of the N-methyl-D-aspartate (NMDA) receptors in the brain (Jean-
Pierre et al., 2000).  Production of pyruvate and D-serine contributes to the energy 
production in astrocytes (Miranda et al., 2002).  Supplementation with D-serine and glycine 
has been shown to reduce the occurrence of seizures in patients with 3-PGDH deficiency 
(de Koning et al., 1998).  Glycine is synthesized from L-serine by the enzymatic action of 
SHMT.  Glycine is an inhibitory neurotransmitter in the brain stem, spinal cord and retina 
(Bruun et al., 1972; Berger et al., 1999).  Glycine binds to glycine receptors on the post-
synaptic membrane, or together with glutamate, it can act as a co-agonist (Johnson et al., 
1987).  Glycine plays an important role for all purines.  Glycine mediated inhibitory effects 
in the spinal cord maintain a delicate balance between glutamate and NMDA induced 
excitatory effect.  Glycine acts as a co-agonist along with glutamate for NMDA receptors 
(Yang et al., 2008).  It is involved in locomotor behavior (Legendre, 2001).  Most proteins 
contain less glycine with the exception of collagens which contains more than 30% (Nelson 
et al., 2005).  Glycine can be converted to glyoxylate by D-amino acid oxidase and 
subsequently oxidized by hepatic lactate dehydrogenase to oxalate (Nelson et al., 2005).  In 
fetal brain development, L-serine regulates the neurotransmission by synthesizing 
neuromodulators and phospholipids (Mitoma et al., 1998).  Alteration in L-serine 
biosynthesis might contribute to severe brain dysfunction in developmental stages.  Taurine 
is beneficial in the management of cardiovascular ailments (Militante et al., 2000).  Taurine 
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keeps potassium and magnesium inside the cell while keeping excessive sodium out, thus it 
works like a mild diuretic (Pop-Busui et al., 2001).  Taurine treatment has been attempted 
for controlling seizures in epileptic patients exhibiting uncontrollable facial twitches (Kirk 
et al., 1994). 
 
1.6. L-serine and Health Benefits 
 Role of L-serine in cell growth and development: conversion of L-serine to glycine 
by SHMT results in the formation of the one-carbon units required for the biosynthesis of 
purine bases, adenine and guanine.  These bases are linked to the phosphate ester of pentose 
sugars that are essential components in the generation of deoxyribonucleic acid (DNA) and 
ribonucleic acid (RNA) and the end products of energy producing metabolic molecules 
such as adenosine triphosphate (ATP) and guanosine-5'-triphosphate (GTP).  L-serine 
conversion to glycine via SHMT provides the same one-carbon units necessary for the 
production of pyrimidine nucleotide, deoxythymidine monophosphate, which is an essential 
component of DNA (McCoy et al., 1956).  L-serine is an integral component of 
phospholipids and serves as a precursor for the biosynthesis of sphingolipids, glycolipids 
and phosphoglycerols.  These are important constituents of cell membranes and they 
regulate signaling pathways for the cell survival and apoptosis (Eagle, 1959; Snell et al., 
1987).  L-serine is an important constituent for brain proteins and protective nerve 
coverings.  L-serine contributes to the production of immunoglobulins and antibodies 
(Munro et al., 1986).  L-serine has a pivotal role in proper functioning of the CNS.  L-
serine is a precursor for the production of several amino acids such as glycine, cysteine, 
phosphatidyl-L-serine, methionine, taurine, and tryptophan.  Tryptophans act as a building 
 33
block in protein synthesis and serves as a biochemical precursor for serotonin biosynthesis, 
a neurotransmitter known to relieve stress, anxiety and depression (Schaechter et al., 1990). 
Some studies show that oral supplementation with L-serine reduces increased levels of 
methionine induced by homocysteine formation and γ-glutamyl transpeptidase activity in 
humans (Verhoef et al., 2004).  Increased levels of plasma homocysteine and γ-glutamyl 
transpeptidase activity are associated with metabolic syndrome, cardiovascular diseases, 
and increased mortality risk (Lee et al., 2007).  γ-Glutamyl transpeptidase plays an 
intermediary role in conversion of leukotriene D4 from leukotriene C4, which triggers the 
formation of P-selectin, thereby contributing to asthmatic and allergic reactions.  Thus the 
inhibition of γ-glutamyl transpeptidase activity promoted by L-serine contributes to its anti-
inflammatory effect (Kanwar et al., 1995).  
 
1.7. L-serine Deficiency and Disease 
 L-serine deficiency leads to slow or delayed cognitive and physical skills, 
psychomotor retardation, seizures, microcephaly, and in some cases nystagmus, 
megaloblastic anemia, cataract and hypogonadism (de Koning et al., 2003).  Microcephaly 
refers to health condition in which the head size is smaller than normal and is caused by 
underdevelopment of the brain (de Koning et al., 1998).  Decrease in 3-PGDH activity 
results in low L-serine levels in both serum and CSF under a fasting state.  Children with L-
serine deficiency develop congenital microcephaly, psychomotor retardation and intractable 
seizures (Klomp et al., 2000).  The gene encoding for 3-PGDH was found to be mutated on 
chromosome one (1p12).  Due to this mutation, valine was substituted for methionine at 
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490 (V490M) position of the enzyme (Pind et al., 2002).  The most common type of L-
serine deficiency results in reduction of 3-PGDH enzyme, through a mutation in the gene 
(Klomp et al, 2000; Pind et al, 2002).  Reduction in 3-PGDH contributes to 
hypomyelination and loss of white matter, characteristic of severe neurological disorder 
(Jaeken et al., 1996).  Alteration in plasma SHMT activity alters L-serine and glycine levels 
in certain areas of the brain resulting in psychiatric disorder (Waziri et al., 1983; Waziri et 
al., 1984).  Low levels of L-serine in CSF but not in plasma are the hall mark for 3-PGDH 
and 3-PSP deficiency (de Koning et al., 2004).  
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CHAPTER 2. HYPOTHESES AND RATIONALE 
 
2.1. Background and Rationale for the Present Study 
 Recently, a study from our laboratory demonstrated that the vasodilator responses in 
the perfused mesenteric vascular bed evoked by ghrelin (a 28 amino acid peptide hormone 
released from the stomach) were not mediated via the classical action of ghrelin on the 
growth hormone secretagogue (GHS) receptor 1a (GHSR1a).  Des-octanoyl ghrelin, a 
linear peptide and a precursor/metabolite of ghrelin with a very low affinity for the 
GHSR1a, evoked similar vasodilator responses as ghrelin.  In addition, several N-terminal 
peptide fragments of des-acyl ghrelin gave a similar vasodilator response as full length des-
acyl ghrelin in an endothelium-dependent manner (Moazed et al., 2009).  The N-terminal 
sequence of des-acyl ghrelin is rich in serine residues (Kojima et al., 2001; Matsumoto et 
al., 2001).  Moreover, it has been shown that N-arachidonoyl L-serine, an 
endocannabinoid-like brain constituent, produces endothelium-dependent vasodilatation of 
rat isolated mesenteric arteries and abdominal aorta (Milman et al., 2006).  These authors 
did not examine whether L-serine per se would evoke endothelium-dependent 
vasodilatation.  Currently, little is known about the cardiovascular effect of L-serine.  The 
major goal of the present work is to address the cardiovascular effects of L-serine in a 
systematic fashion by carrying out a series of studies involving both in vitro and in vivo 
models.  
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2.2 Rationale for in vitro Studies with L-serine  
 The first phase of the work is to examine the effects of L-serine on phenylephrine 
constricted isolated rat mesenteric arteriole preparations.  The third order branches of 
isolated mesenteric arterioles were chosen as the tissue preparation for the following 
reasons: i) it is easy to isolate, ii) it is a representative resistance type blood vessel that 
would reflect the resistance function of the circulation in the whole animal (Christensen and 
Mulvany, 1993), iii) ghrelin, des-acyl ghrelin and their N-terminal fragmented peptides, all 
evoke endothelium-dependent vasodilatation in the mesenteric vascular bed (Moazed et al., 
2009).  iv) Finally, Milman et al., (2006) employed mesenteric arteries to characterize the 
endothelium-dependent vasodilator responses to N-arachidonoyl-L-serine.  Therefore, it is 
logical and rational to begin the first set of studies of the direct vasomotor effects of L-
serine with rat isolated mesenteric arterioles.  
 
2.3. Rationale for in vivo Studies 
 Although it is possible that the efficacy of L-serine as a vasodilator is similar to that 
reported for N-archidonoyl-L-serine in the mesenteric vascular bed, it could be higher or 
absent.  The second stage of the project addresses whether the effect seen in the in vitro 
preparation in a resistance type arteriole would reflect as the likely change in the in vivo 
model following acute infusions of L-serine.  Therefore, we examined the effects of an 
acute L-serine bolus infusion on the MAP and HR in normotensive and hypertensive rats.  
It is important that the study address the overall contribution and the effects of L-serine for 
the likely effects on BP particularly in the hypertensive rat models.  These studies if 
successful would support the in vitro observations.  It is also important to examine whether 
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the effects of L-serine is mimicked/shared by its D-isomer, D-serine, or its metabolite, 
glycine, or its precursor, L-threonine.  This is in order to assess whether these amino acids 
in fact mediate the effects of L-serine subsequent to its bioconversion in vivo, or these 
related amino acids exert effects similar to L-serine via activating signaling mechanisms 
recruited by L-serine.  If D-serine exhibits similar characteristics to L-serine, the 
cardiovascular effects of L-serine are not stereospecific.  Thus, comparative studies with D-
serine, glycine and threonine become vital to distinguish whether the effects of L-serine 
have selectivity and specificity.   
 
2.4. Rationale for Regional Hemodynamic Studies 
 Once the effects of L-serine on MAP and HR are known, it is then important to 
determine the contribution of different vascular beds to the observed systemic effect.  It is 
possible to monitor L-serine evoked changes in blood flow and vascular resistance in 
different vascular beds using the perfused microsphere technique.  It is also feasible to 
calculate the changes in TPR before and after infusion of L-serine.  Accordingly, this study 
will be the third in series of experiments assessing the in vivo effects of L-serine on 
different vascular beds besides the mesenteric vascular bed to account for the observed 
changes in systemic hemodynamic responses.  
 
Finally and most importantly, the data from our laboratory and others have led to the 
conclusion that in the perfused mesenteric vascular bed, N-terminal peptide fragments of 
ghrelin evoke endothelium-dependent vasodilatation (Moazed et al., 2009).  N-archidonoyl-
L-serine also evokes endothelium-dependent vasodilatation in mesenteric arteries (Milman 
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et al., 2006).  Interestingly, ghrelin-evoked hypotensive response was higher in L-NAME 
treated hypertensive rats.  Pretreatment with a combination of apamin plus charybdotoxin, 
small and intermediate conductance KCa channel inhibitors, abolished the hypotensive 
responses to ghrelin (Shinde et al., 2005). There are no studies on the direct cardiovascular 
effects of L-serine either under in vitro or in vivo conditions.  Based on the above, the 
following working hypotheses are formulated.      
 
2.5. Working Hypothesis  
 L-serine evokes concentration-dependent changes in phenylephrine constricted 
mesenteric arterioles that is endothelium dependent.  This action is mediated by the 
activation of Ca2+ dependent potassium channels present on the endothelium.  
 
L-serine per se lowers mean arterial pressure (MAP) following its acute intravenous 
administration.  The hypotensive effects of L-serine are greater in spontaneously 
hypertensive rats (SHR) and in rats rendered hypertensive by chronic inhibition of NOS by 
treatment with L-NAME, than in normotensive rats. 
 
The fall in MAP in hypertensive rat is due to reduced total peripheral resistance (TPR), a 
summation of the fall in regional vascular resistance occurring in many vascular beds 
including the mesenteric vascular bed. 
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2.6. Experimental Strategy 
 
2.6.1. Choice of Animal Models and Choice of Tissue: 
 All studies were performed in 12 to 14 week old male Sprague-Dawley rats, Wistar-
Kyoto rats (WKY), SHR or Sprague-Dawley or WKY rats rendered hypertensive by L-
NAME treatment for 5 days (Ribeiro et al., 1995).  SHR is an ideal animal model, which 
mimics human essential hypertension (Okamoto et al., 1963).  The origin of SHR is from 
mating with brother and sister in a continued selection fashion originated from outbred 
WKY male with elevated BP and female with slightly elevated BP.  So it is appropriate to 
consider that WKY rats serve as normotensive control strain for SHR strain (Yukio et al., 
1973).  In SHR, the increase in BP is due to an increase in vascular resistance.  Alteration 
in neurohormonal regulation also contributes to hypertension in these animals (Yukio et al., 
1973).  Since neuroendocrine dysregulation also appears to play a key role in the 
development of essential hypertension in humans, the SHR model is the closest animal 
model to human essential hypertension (Folkow et al., 1972).  The SHR strain responds 
well to most of the antihypertensive agents used in human (Yamori, 1971).  Thus, SHR is 
considered widely as a good laboratory model for screening antihypertensives (Okamoto, 
1969).  Previous studies have established that between 12 and 14 weeks of age, the 
elevation in MAP reaches a plateau and it would be the ideal age group to perform studies 
for lowering BP in the established phase of hypertension (Okamoto et al., 1973).  The 
chronic L-NAME-induced hypertensive model Sprague-Dawley was chosen because 
ghrelin, showed an exaggerated hypotensive response in L-NAME treated rats (Shinde et 
al., 2005).  The rationale for employing mesenteric arterioles for the in vitro studies was 
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highlighted earlier.  Thus, the study design takes into consideration investigations at the 
following levels:   
i) In vitro Studies – wire myography studies to examine the effects of L-serine on 
phenylephrine constricted third order branches of rat isolated mesenteric 
arterioles.  
ii) In vivo Studies – The effects of acute intravenous infusion of L-serine in SD, WKY 
and SHR strains, SD and WKY rendered hypertensive by chronic treatment with 
L-NAME.  Besides L-serine, the effects of comparable doses of D-serine, 
glycine and L-threonine will be determined.  
iii)  Regional Hemodynamic Studies – This will be performed in both hypertensive rat 
models as well as control normotensive strains to determine the vascular tissues 
targeted by L-serine. Besides changes in regional blood flow, perfused 
microsphere technique estimates changes in regional vascular resistance, TPR in 
the whole animal preparation.    
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CHAPTER 3. METHODS 
 
3.1. Animals  
 The present study was approved by our University Review Committee and 
conformed to the Guide for the Care and Use of Laboratory Animals stipulated by the 
Canadian Council on Animal Care and the National Institute of Health (NIH) publication 
No. 85-23.  Twelve to fourteen week-old male Sprague-Dawley rats (350 to 380g), Wistar-
Kyoto (WKY) rats (300 to 350g) and SHR (250 to 270g) were obtained from Charles River 
(St. Constant, Quebec, Canada).  One group of Sprague-Dawley and WKY rats received 
nitric oxide synthase (NOS) inhibitor, NG nitro L-arginine methyl ester, L-NAME (0.7 
mg/ml in drinking water ad libitum) for 5 to 7 days (Shinde et al., 2005; Desai et al., 2006).  
All other rats received plain water.  In the present study, chronic L-NAME treated WKY 
and SHR served as hypertensive rat models, while untreated WKY and Sprague-Dawley 
rats served as normotensive control groups.  
 
3.2. Materials  
 The chemicals used in these experiments and their sources are listed as follows: 
Acetylcholine (ACh), barium chloride (Ba2+), indomethacin, L-serine, D-serine, glycine, L-
threonine, NG nitro L-arginine methyl ester (L-NAME) and (+)-5methyl-10,11-dihydro-
5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801), ouabain, phenylephrine 
hydrochloride (PE) were obtained from Sigma-Aldrich Canada Ltd. (Oakville, ON., 
Canada).  Apamin and charybdotoxin (ChTX) were from EMD Biosciences Inc. (La Jolla, 
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CA, USA).  1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34) was a gift from 
Dr. Heike Wulff, University of California at Davis.  Thiopental sodium was obtained from 
Abbott Laboratories Ltd (Saint Laurent, Quebec, Canada).  U46619 and another lot of L-
serine were purchased from Calbiochem (San Diego, CA, USA).  Fluorescent microspheres 
were purchased from Molecular Probes, Inc, (Eugene, Oregon, U.S.A.).  Fluorescent 
microspheres are made up of polystyrene with a diameter of 10 to 15 µm.  Fluorescent 
microspheres are available with different fluorescent dyes colors, whose fluorescence is 
well resolved from each other (Glenny et al., 1993).  
Note:  Charybdotoxin was used in place of TRAM-34 for in vivo studies since   
charybdotoxin is soluble in water where as TRAM-34 is insoluble in water, and soluble in 
dimethyl sulfoxide.  
 
3.3. Experimental Procedures 
 
3.3.1. In Vitro Study using Wire Myograph   
 The rats from normotensive Sprague-Dawley and Sprague-Dawley rats rendered 
hypertensive by pretreatment with L-NAME (0.7 mg/ml in drinking water for 5 to 7 days) 
were anaesthetized with an intraperitoneal injection of thiopental sodium (100 mg/kg, 
Shinde et al., 2005; Desai et al., 2006).  Laparotomy was performed and the mesenteric bed 
was located.  The rat mesentery was carefully excised, and cleaned of adherent tissues.  A 
section of mesentery about 100 mm distal to the pylorus was tied with the help of two 
threads, rapidly removed and placed in oxygenated ice-cold Krebs buffer, the composition 
given below. With the aid of a dissection light microscope, the third order arterioles (inner 
 43
diameter ~120 µm) were carefully isolated.  Six to eight rings (~2 mm length) were cut 
from the third order branches of the isolated blood vessels were mounted in wire myograph 
apparatus for isometric tension measurements.  Rings were suspended between a 
micropositioner and force transducer with two stainless steel wires (40 µm diameter) in the 
myograph chamber (Model 610M Multi Wire Myograph System, Danish Myo technology, 
Denmark).  Resting tension (1.5 mN) was maintained for an initial equilibration period of 1 
hr in Krebs buffer of the following composition (in mmol/L): 120, NaCl; 1.8, CaCl2; 4.8, 
KCl; 1.2, MgCl2; 1.2, KH2PO4; 25, NaHCO3; 10, glucose; pH 7.4 gassed with 95% O2, 5% 
CO2 and maintained at 370C (Buus et al., 1994).  The rings were washed every 15 min in 
Krebs buffer.  Isometric tension was recorded using a Powerlab data acquisition system 
(AD Instruments Pvt. Ltd., Sydney, Australia).  Certain vessels were mounted without 
scratching the intimal surface while placing the hooks to ensure that the endothelium was 
not damaged.  In some vessels endothelium was damaged by passing a thin wire /hair 
before they were mounted in the myograph.  The endothelium was considered to be 
denuded if the vasodilator response to ACh was reduced to ≤ 10% of its original level (>90 
%) with no change in the vasodilator response to sodium nitroprusside (SNP).  The dose-
response (DR) relationship for L-serine (1 µmol/L to 500 µmol/L) and ACh (1 pmol/L to 
10 µmol/L) were determined in these vessels after sustained tonic vasoconstrictor response 
to a fixed concentration (≈ EC90) of α1 selective agonist, phenylephrine (PE, 10 µmol/L) 
was attained.  In some experiments, instead of PE, vasoconstriction was attained using 
either the thromboxane analog, U46619 (1 µmol/L) or subjected to a depolarizing stimulus 
with potassium chloride (KCl, 80 mmol/L).  In select experiments, mesenteric arterioles 
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isolated from L-NAME pretreated rats with intact endothelium that were preconstricted 
with PE, small increments in KCl were added to the organ baths such that the final 
concentration of KCl in the buffer would be 9.8, 12.8, 15.8 and 18.8 mmol/L and the 
changes in dilator responses were determined.  When investigating the effects of various 
inhibitors such as a non-selective cyclooxygenase (COX) inhibitor, indomethacin (10 
µmol/L), or apamin (SKCa inhibitor, 1 µmol/L) or TRAM-34 (IKCa inhibitor, 1 µmol/L), or 
ouabain (Na+/K+/ATPase inhibitor, 20 µmol/L), or Ba2+ (Kir channel inhibitor, 50 µmol/L), 
they were added, either alone or in a combination as indicated, to the organ baths 20 min 
prior to the addition of PE.  The concentrations of the above agents were chosen based on 
data established in an earlier study (Edwards et al., 1998).  These agents were maintained 
until the responses to increasing concentrations of either L-serine or ACh were determined 
in vessels isolated from both normotensive control and chronic L-NAME treated rats.  
 
3.3.2. In Vivo Studies 
 Rats from normotensive Sprague-Dawley, WKY, Sprague-Dawley and WKY rats 
rendered hypertensive by pretreatment with L-NAME (0.7 mg/ml in drinking water for 5 to 
7 days) and SHR groups were considered for the present study. Rats were anaesthetized 
with an intraperitoneal injection of thiopental sodium and allowed to breathe spontaneously 
through a tracheal cannula.  In the present study the femoral artery was cannulated and 
connected to a pressure transducer to record the changes in MAP and HR using the 
PowerLab data acquisition system (AD Instruments Pvt. Ltd. Sydney, Australia).  Left or 
right femoral vein was cannulated to administer drugs as bolus injections in a limited 
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volume of 0.4 ml/kg of various agents prepared in saline and the pH was adjusted to 7.3.  
After ensuring that the MAP and HR had stabilized, the responses to bolus infusions of 
either L-serine (between 0.1 and 3.0 mmol/kg) or ACh (0.1 to 10 nmol/kg) were 
determined.  During experiments sufficient time was given between each response for the 
MAP to recover to the resting baseline.  To inhibit selectively the EDHF mediated 
responses in vivo, the animals were subjected to slow infusions of a combination of small 
conductance Ca2+dependent K+ channel (SKCa) inhibitor apamin (75µg/kg) followed by an 
intermediate conductance Ca2+ dependent K+ channel (IKCa) inhibitor, charybdotoxin 
(ChTX, 75 µg/kg).  The total infusion time period was maintained for 15 min with the help 
of an infusion pump (Harvard Apparatus, Quebec, Canada).  We observed an elevation of 
MAP within 5 min following the slow infusion of apamin and ChTX, and it returned to a 
level slightly above the resting MAP level in about 30 min.  After 45 min, we determined 
the dose-response (DR) curves to ACh and found to be optimal since the blockade of 
hypotensive responses to ACh was highly significant particularly in L-NAME treated rats.  
These data confirmed that combined infusion of apamin and ChTX at the dose level 
infused, blocked EDHF dependent fall in MAP evoked by ACh.  Then, the effects of 
comparable doses (between 0.1 and 3.0 mmol/kg) of L-serine, D-serine, glycine, and L-
threonine were determined.  In subsequent experiments, the maximum dose of L-serine was 
limited to 2.0 mmol/kg in the chronic L-NAME treated rats, after finding that recovery to 
baseline was difficult following the profound fall in MAP attained with the 3.0 mmol/kg 
doses.  The responses to either glycine or L-serine were also determined before and 30 min 
 46
after slow infusion over a period of 15 min of the NMDA receptor antagonist, MK-801 (75 
mg/kg. i.p.).  
 
Studies were also performed in a selected groups of normotensive Sprague-Dawley and 
WKY rats in which the effect of increasing doses (0.3 to 3.0 mmol/kg, iv.) of glycine 
infusion was examined both prior to and 1 hr after acute infusion of L-NAME (100 mg/kg, 
i.v. given over a period of 10 min) to compare the responses to glycine infusion in chronic 
L-NAME treated hypertensive WKY group vs. acute L-NAME treated hypertensive rats. 
The acute dose of L-NAME was determined from previous work (Rees et al., 1990). 
 
3.3.3. Regional Hemodynamic Study 
 For this study twelve -week old male WKY rats (300 to 350g) and SHR (250 to 
270g) were obtained from Charles River (St. Constant, Quebec, Canada). After one week 
acclimatization one group of WKY rats received L-NAME (0.7 mg/ml in drinking water 
given ad libitum) for 5 to 7 days and other rats received plain water.  In this experiment, 
SHR and L-NAME pretreated rats served as hypertensive rat models and WKY rats served 
as the control group. 
 
3.3.3.1. Surgical Procedure for Regional Hemodynamic Study 
 Rats were anesthetized with thiopental sodium (100 mg/kg, i.p.).  Body temperature 
was maintained at 370C with the help of a controlled heating pad.  The trachea was 
cannulated to allow spontaneous breathing.  The right femoral artery was cannulated with 
polyethylene tubing (PE-20) and connected to a pressure transducer to record changes in 
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MAP and HR using a PowerLab data acquisition system (AD Instruments Inc., Sydney, 
Australia).  The left femoral artery was cannulated and connected to a reciprocal syringe 
pump (Havard Apparatus, Quebec, Canada) for collecting the reference blood sample.  The 
left femoral vein was cannulated to administer saline (vehicle) or L-serine (prepared in 
saline, pH adjusted to 7.3) either in the presence or absence of apamin plus ChTX.  The 
total volume of infusion of all these agents was limited to maximum volume of 0.4 ml/kg.  
The right carotid artery was cannulated with saline filled PE-50 tubing connected to a 
pressure transducer.  The carotid cannula was subsequently guided through the common 
carotid artery into the left ventricle, which was confirmed by the characteristic ventricular 
pressure wave form (Glenny et al., 1993; Gervais et al., 1999).  
 
3.3.3.2. Hemodynamic Measurement using Fluorescent Microspheres 
 Hemodynamic measurements were performed using fluorescent microsphere 
distribution technique (Glenny et al., 1993; Gervais et al., 1999; Deveci et al., 1999).  Four 
different colors (green, yellow, red-orange and carmine) of 15 μm diameter fluorescent 
microspheres (FluoSpheres®) were purchased and stored at 40C.  The combination of 
microspheres used in a single study was determined on the basis of their 
absorption/emission maxima wavelength (nm) to avoid spill over (Hakkinen et al., 1995; 
De Angelis et al., 2005).  To ensure steady MAP and HR, enough time (30 min) was given 
after all cannulation.  Microspheres were then sonicated and vigorously vortexed for 2 to 3 
min just before use to avoid sedimentation, then diluted to a final volume of 0.3 ml. 80,000 
to 100,000 microspheres were suspended in 0.3 ml of 0.9% saline containing 0.01% w/v 
Tween 20.  Microspheres were vortexed and immediately injected into the left ventricle 
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through the carotid artery cannula over a period of 20 seconds and flushed with 0.3 ml 
saline over a period of 20 seconds.  Concurrently, for the reference blood sample, blood 
was withdrawn from femoral artery, downstream from the site of microsphere injection, at 
a rate of 0.5 ml/min, starting 10 seconds prior to simultaneous infusion of test drug and 
microspheres by injection and continued for a further 70 seconds.  Reference blood sample 
was transferred to a tube with heparin (50 unit/ml), mixed well and kept on ice (Ishise et al., 
1980).  This procedure was carried out first for vehicle infusion, then L-serine (1 mmol/kg 
dose) after 10 min to confirm reproducibility, by employing a different colored microsphere 
(Glenny et al., 1993).  The same procedure was employed to evaluate the effect of L-serine 
in presence of apamin plus ChTX (75 μg/kg) combination and they were infused slowly 
over a period of 15 min with the help of an infusion pump.  After 30 min responses to L-
serine infusion was determined.  The experiment was terminated by giving an overdose of 
thiopental 10 min after the last microsphere injection.  Then various organs/tissues such as 
heart, left as well as right kidney, liver, lungs, spleen, brain, stomach, small and large 
intestine, diaphragm, skeletal muscle and pancreas were collected in whole or part to 
quantify the fluorescence intensity of the dye from microspheres captured in each tissue. 
Briefly, the organs were removed and rinsed with cold saline, patted dry, weighed, and 
placed in 15 ml glass tubes.  Both the reference blood samples and tissues were digested for 
24 to 48 hr in 3 to 4 ml of potassium hydroxide (KOH, 4.0 M) solution per gram of tissue.  
The tubes were shaken thoroughly every few hours.  After 48 hour, the microspheres were 
recovered by centrifuging for 20 min at a speed of 2000 x g (Precision, Durafuge 100, 
Winchester, VA, Van Oosterhout et al., 1995).  Supernatants were carefully removed 
leaving < 1ml in each glass tube.  The pellet with microspheres in each glass tube was 
 49
rinsed with 9 ml of 0.25% Tween 80 in demineralized water at 600C, vortexed, centrifuged 
again at a speed of 2000 x g for 20 min.  A final rinse with demineralized water without 
Tween was carried out and the supernatant was carefully removed leaving 1ml.  3 ml of 
Cellosolve acetate (2-ethoxy-ethyl acetate), a solvent, was then added to the tubes, vortexed 
thoroughly and allowed to stand for ≥ 4 hours to dissolve the polystyrene coating of the 
microspheres, which were then centrifuged again at 2,000 x g for 10-15 min (Oosterhout et 
al., 1995).  Tubes were vortexed after 4 hr, then centrifuged at 2000 x g for 10-15 minutes. 
The supernatant was removed and utilized for the measurement of fluorescence.  To 
calculate the blood flow rate per tissue sample (ml/min/g), the following formula was used: 
Fi = (Ii)(R)/Iref where: Fi = flow to individual sample (ml/min), Ii = fluorescence intensity of 
the sample, R = reference sample withdrawal rate (ml/min), Iref = fluorescence intensity of 
the reference blood sample.  MAP (mmHg), HR (beats/min), CO (ml/min) = total number 
of injected microspheres * reference sample withdrawal rate/number of microspheres in the 
reference blood sample, cardiac index (CI, ml/min/kg) = CO/body surface area, TPR 
(mmHg/ml/min) = MAP/CO, TPR index (TPRI, mmHg/ml/min/kg) = MAP/CI, organ 
vascular resistance (mmHg/ml/min/g) = average MAP during microsphere infusion/local 
blood flow to individual organs were calculated as previously described (Granstam et al., 
1998; Sampaio et al., 2003; De Angelis et al., 2006; Giancarla et al., 2007). 
 
3.3.3.3. Measurement of Fluorescence  
 F-2500 fluorescence spectrometer (Hitachi, Tokyo, Japan) was used to measure 
fluorescence intensity at excitation and emission wavelengths between 350 to 750 nm using 
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5 nm slit width.  Each individual sample was read in a 5 ml quartz cuvette in duplicate 
including reference blood samples (Oosterhout et al., 1995; Granstam et al., 1998; Sampaio 
et al., 2003; De Angelis et al., 2006; Giancarla et al., 2007). 
 
3.4. Statistical Analysis 
 The vasodilator responses to L-serine and ACh were determined in both 
endothelium intact and denuded mesenteric arterioles isolated from normotensive control 
and L-NAME treated rats.  Data represents the mean ± SEM of (n = 20 arterioles) from 8 
rats. Difference between the means of both control and L-NAME treated vs. endothelium 
intact and denuded groups considered significant by a one-way analysis of variance 
followed by Tukey’s post hoc test.  The differences were considered significant when p < 
0.05. 
 
The change in MAP following infusion of each dose was plotted to generate the dose-
response (DR) curves to L-serine, ACh and respective amino acids.  The data are expressed 
as mean ± SEM (n = 5 to 7).  Differences between the means of two groups were tested for 
significance by a one-way analysis of variance followed by Tukey’s post hoc test.  The 
differences were considered significant when p < 0.05. 
 
The results obtained in hemodynamic studies are expressed as mean ± SEM of experiments 
performed in 5 to 7 rats for each group.  The differences between mean values were 
analyzed by one-way analysis of variance for repeated measures followed by Bonferroni’s 
multiple comparison tests and considered significant when the values were p < 0.05.  
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CHAPTER 4. RESULTS 
4.1. In Vitro Studies 
 
4.1.1. Vasodilator Effect of L-serine 
 L-serine evoked vasodilator effect was concentration-dependent in PE constricted 
endothelium intact arterioles isolated from normotensive and hypertensive rats.  L-serine 
mediated vasodilator response was higher in mesenteric arterioles isolated from chronic L-
NAME treated rats.  A representative experiment shows the comparison of dose dependent 
vasodilator response to L-serine and ACh in endothelium-intact vessels (Figure 3 a and b). 
Their lack of response in endothelium-denuded vessels, isolated from a chronically L-
NAME treated rat (Figure 3 c and d).  L-serine mediated vasodilator response was slower 
and maximal (Emax) response was lower compared to ACh (Figure 3 a, b, c and d).  In 
endothelium denuded mesenteric arterioles both ACh and L-serine failed to evoke 
vasodilatation, even at very high concentrations (Figure 3 c and d).  In L-NAME treated 
group, the Emax for L-serine (40 ± 3 %) in endothelium-intact vessels was significantly 
shifted to the left (p < 0.01) compared to control group with Emax (20 ± 3%, Figure 4 a).  In 
the same L-NAME treated group, the Emax for ACh (93 ± 2 %) in endothelium intact 
vessels was significantly shifted to the right compared to control group with Emax (79 ± 3 
%, Figure 4 b).  A graphical representation of the Emax values for L-serine and ACh are 
compared in endothelium intact and denuded mesenteric arterioles (Figure 5 a and b).  In 
endothelium-intact arterioles isolated from L-NAME treated group, incubation with a 
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combination of either apamin plus TRAM-34 or ouabain (Na+ pump inhibitor, 20 µmol/L) 
plus Ba2+ (Kir channel inhibitor, 50 µmol/L) abolished the responses to both L-serine and 
ACh, whereas addition of either the non selective COX inhibitor, indomethacin (10 
µmol/L), or apamin (SKCa inhibitor, 1 µmol/L) or TRAM-34 (IKCa inhibitor, 1 µmol/L) 
alone failed to affect the Emax (Figure 5 c and d).  We observed similar responses to L-
serine and ACh when another vasoconstrictor agonist, TXA2 agonist, U46619 (1 µmol/L), 
was used to compare the Emax values for L-serine (40 %) and ACh (90 %) instead of PE; 
in contrast, L-serine failed to evoke vasodilatation in arterioles preconstricted with a 
depolarizing concentration of KCl (80 mmol/L), (Figure  6).  Small increments of KCl 
between 10 and 20 mmol/L in PE constricted arterioles isolated from L-NAME treated rats 
evoked a concentration-dependent vasodilatation, and addition of L-serine failed to enhance 
further vasodilator response; incubation with a combination of Ba2+ (Kir channel inhibitor) 
and ouabain (Na+ pump inhibitor) abolished the responses to K+ but not the combination of 
apamin plus TRAM-34 (Figures 7 and 8).    
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Figure 3.  A representative tracing that demonstrates the pattern of vasodilator responses to 
cumulative addition of increasing concentrations of either L-serine (1 to 500 µmol/L) or 
ACh (0.1 pmol/L to 100 µmol/L) in endothelium-intact (ENDO [+] a and b) or 
endothelium-denuded (Endo [-] c and d) third order branches of mesenteric arterioles 
constricted with PE (10 µmol/L) in vitro after isolation from a 12 week old male Sprague-
Dawley rat that received chronic L-NAME treatment (0.7 mg/ml, in drinking water) for five 
days.  W - denotes when the tissues were washed in normal Krebs buffer to attain recovery.  
Similar responses were noted in vessels from 8 chronic L-NAME treated rats.   
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Figure 4. The line graphs compare the concentration curve (CR) curves to L-serine (a) 
determined in PE constricted mesenteric arterioles isolated from either normotensive 
control group ({) or chronic L-NAME treated hypertensive rats (●) with intact 
endothelium.  The lack of responses to L-Serine in endothelium-denuded vessels in both 
control (U) and chronic L-NAME treated (S) vessels are also shown.  The CR curves to 
ACh (b) determined in either the control group (□) or chronic L-NAME treatment group 
() with intact endothelium or the lack of responses in endothelium-denuded vessels in 
control (V) and chronic L-NAME treated (T) vessels are shown.  Each data point 
represents mean ± SEM of n > 20 arterioles isolated from > 8 rats from control and chronic 
L-NAME treatment groups.  *p < 0.05 and **p < 0.01 compared to data point in the control 
group.  
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Figure 5. The bar diagram compares the maximal vasodilator response (Emax) to 200 
µmol/L L-Serine (a) or 10 µmol/L ACh (b) in both control and chronic L-NAME treated 
rats in either endothelium-intact (ENDO [+]) or endothelium-denuded (Endo [-]) PE 
constricted mesenteric arterioles.  The Emax values for L-serine (c) and ACh (d) attained in 
endothelium intact ([Endo [+]) arterioles isolated from chronic L-NAME treated rats either 
in the absence (Control - Con) or the presence of indomethacin (10 µmol/L, Indo), apamin 
(1 µmol/L, Apa) or TRAM-34 (1 µmol/L, Tram) or a combination of apamin plus TRAM-
34 (1 µmol/L of each Apamin plus Tram-34) or a combination of barium chloride (Ba2+ 50 
µmol/L) and ouabain (Ouab 20 µmol/L) are compared. Each data point is a pooled value of 
mean ± SEM from 20 preparations isolated from 8 different rats.  **p < 0.001 compared to 
the respective data in endothelium-intact (Endo [+]) group.  
 56
 0
25
50
 **
L-S
PE
   L-S
U46619
 L-S
 KCl
%
 V
as
od
ila
ta
tio
n
 
 
Figure 6. The maximal vasodilator responses (Emax) to L-serine (L-S, 500 μmol/L) 
attained in either phenylephrine (PE 10 μmol/L) or thromboxane analog, U46619 (1 
μmol/L) or high potassium chloride (KCl, 80 mmol/L) constricted third order branches of 
mesenteric arterioles maintained in wire myograph after isolation from chronic L-NAME 
treated rats.  Each data point is mean ± SEM of 5 separate experiments using vessels 
isolated from four L-NAME treated rats.  **p < 0.01 compared to the responses to L-S data 
in the presence of either PE or U46619. 
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Figure 7. The data of a typical experiment of concentration dependent vasodilator 
responses to cumulative increases in either L-serine (Panel a: L-Serine 50 to 200 μmol/L) 
or KCl (Panel b: KCl 9.7 to 18.7 μmol/L followed by L-serine 100 to 500 μmol/L) in PE 
(10 μmol/L) constricted endothelium-intact mesenteric arterioles isolated from L-NAME 
treated rat.  Panel c shows that in the same vessel, after pretreatment with apamin plus 
TRAM-34 (1 μmol/L) addition of the first dose of KCl (9.7 mmol/L) evoked vasodilatation 
whereas when the tissues were washed and incubated with a combination of Ba2+ (50 
μmol/L) and ouabain (20 μmol/L), either the addition of KCl (9.7 to 18.7 mmol/L) or ACh 
(10 μmol/L) failed to elicit vasodilatation.  
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Figure 8. The bar diagram shows the pooled mean ± SEM data from 4 separate 
experiments comparing the maximal vasodilator responses to KCl (18.7 mmol/L) attained 
in PE (10 μmol/L) constricted arterioles isolated from L-NAME treated rats either before 
(control □) or after apamin plus TRAM-34 (■) or ouabain plus Ba2+ () pretreatments in 
vitro. **p < 0.01 compared to the responses to KCl either in the absence or presence of 
apamin plus TRAM-34. 
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4.2. In vivo Studies 
 
4.2.1. Acute Hemodynamic Effect of L-serine  
 As a follow up our in vitro observation, the acute effect of a bolus dose of L-serine 
infusion was examined in normotensive and L-NAME treated hypertensive rats.  In the L-
NAME treatment group, basal MAP (135 ± 6 mmHg; n = 12) was significantly higher (P < 
0.01) compared to the normotensive control group (93 ± 8 mmHg; n = 12, Table 3).  L-
serine evoked a dose-dependent fall in MAP in both control and L-NAME treatment 
groups, but the effect was abrupt and more profound in the L-NAME treatment group 
(Figure 9).  A typical experiment shows a combination of apamin plus ChTX infusion 
abolished the hypotensive response to L-serine in control rat (Figure 9 b).  Saline infusion 
alone failed to affect BP in either group of animals.  The entire experiment was 
reproducible in both the control and L-NAME treated group.  In chronic L-NAME 
treatment rats, the fall in MAP was observed at a concentration of 0.3 mmol/kg and the 
maximal fall attained at 3.0 mmol/kg which was much higher (140 mmHg to 50 mmHg) in 
this group of rats than control rats (Figure 9 c).  A combination of apamin plus ChTX 
infusion abolished the responses to L-serine up to 2.0 mmol/kg but in higher concentration 
(3.0 mmol/kg) we observed a fall in MAP which was much lower compared to control 
response (Figure 9 c and d).  ACh (0.1 to 10.0 nmol/kg) infusion evoked a dose-dependent 
fall in MAP in both control and L-NAME treatment groups (Figure 10 a and c).  The dose-
dependent fall in MAP evoked by ACh was abolished only in L-NAME treatment but not in 
control rats that received apamin plus ChTX pretreatment since NO pathway is blocked by 
inhibition of NOS by L-NAME pretreatment (Figure 10 b and d).  Data from several 
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experiments revealed that the fall in MAP evoked by L-serine was much lower in the 
normotensive control group of rats compared to ACh, with a minimal rightward shift in the 
DR curve after pretreatment with apamin plus ChTX combination (Figure 11 a and b).  
Pretreatment with apamin plus ChTX abolished the responses to L-serine at concentrations 
range up to 2.0 mmol/kg, and the rightward shift in the DR curve to L-serine was much 
higher compared to ACh in L-NAME pretreated rats (Figure 11 c and d).  L-serine and 
ACh evoked fall in MAP were accompanied by a non-significant increase in HR in both 
normotensive control and L-NAME pretreated hypertensive rats (Table 3). 
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Table 3. Comparison of mean arterial pressure (MAP, mmHg) and heart rate (HR, beats per 
minute) recorded before and 30 seconds after infusion of L-serine (2 to 3 mmol/kg) in 12 week 
old male Sprague-Dawley and L-NAME pretreated Sprague-Dawley rats. 
    
Baseline L-serine Strain 
MAP HR MAP HR 
Sprague-Dawley 
 
108 ± 5 352 ± 9 79 ± 3† 376 ± 8 
Sprague-Dawley 
(L-NAME treated) 
139 ± 4* 330 ± 6 45 ± 3†† 380 ± 7 
 
Each data point is mean ± SEM of n = 7 to 9 rats/group. 
*p < 0.05 vs. Sprague-Dawley (Control) group; †p < 0.05; ††p < 0.01 vs. respective baseline 
value in the same group prior to infusion of L-serine. 
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Figure 9. A typical experiment compares the fall in MAP to acute i.v. infusion of various 
doses of L-serine (0.1 to 3.0 mmol/kg) in a control rat before (a) and 45 min after (b) and in 
a chronic L-NAME (0.7 mg/ml, in drinking water for five days) treated rat before (c) and 
45 min after (d) the infusion of apamin plus ChTX (75 µg/kg each).  
 
 63
 40
60
80
100
120
140
10.00 20.00 30.000.0
0.1 0.3 1.0 3.0 10.0
40
60
80
100
120
140
10.00 20.00 30.00
0.1 0.3 1.0 3.0 10.0
0.0
40
60
80
100
120
140
0.0 20.00 30.0010.00
ACh (nmol/kg)
0.1 0.3 1.0 3.0 10.0 SNP
10.0
nmol/kg
M
AP
 (m
m
H
g)
Time (min)
(b)
(d)
40
60
80
100
120
10.00 20.00 30.0
0.1
ACh (nmol/kg)
0.3 1.0 3.0
0.0
(a)
(c)
 
 
Figure 10. A typical experiment compares the fall in MAP to acute i.v. infusion of various 
doses of ACh (0.1 to 10.0 nmol/kg) in a control rat before (a) and 45 min after (b) and in a  
chronic L-NAME treated rat before (c) and 45 min after (d) the infusion of apamin plus 
ChTX (75 µg/kg each).  
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Figure 11. The dose response relationship between L-serine (a - before [{] and after [U] 
apamin plus ChTX) or ACh (b - before [□] and after [V] apamin plus ChTX) infusion and 
the maximal fall in MAP attained in the control group.  The DR relationship between L-
Serine (c - before [●] and after [S] apamin plus ChTX) or ACh (d - before [] and after 
[T] apamin plus ChTX) and the maximal fall in MAP in L-NAME treated hypertensive 
rats.  Each data point is mean ± SEM of n > 8 rats per each group.  *p < 0.05 and **p < 
0.01 compared to the data point in the control group.  
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4.2.2. Acute Hemodynamic Effect of L-serine, D-serine, Glycine and L-threonine 
 After establishing the acute hemodynamic effects of L-serine, it was important to 
examine whether the precursor of L-serine, L-threonine or its metabolites such as D-serine 
and glycine, would evoke effects like L-serine in normotensive and hypertensive rat 
models.  For this study we considered two normotensive rat models, Sprague-Dawley and 
WKY rats, and two hypertensive rat models namely, L-NAME pretreated hypertensive 
Sprague-Dawley and WKY rats, and SHR strains.  In normotensive Sprague-Dawley and 
WKY strains, the basal MAP and HR were similar.  In L-NAME pretreated hypertensive 
Sprague-Dawley and WKY rats and SHR MAP was higher (142 ± 3 mmHg, 149 ± 4 
mmHg and169 ± 4 mmHg, Table 4).  Pooled data from several experiments revealed that 
acute infusion of comparable doses of D-and L-serine evoked reversible, dose dependent 
fall in MAP in both normotensive and hypertensive rat models. A representative 
experiment performed in parallel to demonstrate the fall in MAP evoked by D-and L-serine 
in a normotensive WKY rat (Figure 12 a), chronic L-NAME pretreated hypertensive WKY 
rat (Figure 12 b) and SHR strain (Figure 13 a).  It is evident from all these experiments, the 
responses to L-serine was much higher and more pronounced at each incremental doses 
compared to D-serine (Figure 12 a, b and 13 a).  The profound fall in MAP after infusion of 
3.0 mmol/kg required that the dose be limited to 2.0 mmol/kg in L-NAME pretreated rats.  
This was because the return of MAP to baseline was difficult after administering this dose  
in hypertensive rats (Figure 12 b and Figure 14 c).  Although the baseline MAP was higher 
in the SHR strains (169 ± 4 mmHg) compared to L-NAME pretreated hypertensive WKY 
rats (149 ± 4 mmHg) the fall in MAP evoked by D-and L-serine was relatively lower in 
SHR strain in comparison to L-NAME pretreated hypertensive WKY rats (Figure 12, 13 
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and Table 4).  Data gathered from several D-and L-serine DR curves confirmed that the BP 
lowering effect of L-serine was more potent and efficacious at each incremental dose 
compared to D-serine.  The maximal BP lowering effect of L-serine occurred in the 
following rank order in different strains: chronic L-NAME treated WKY > SHR > WKY ≥ 
Sprague-Dawley rats (Figure 14).  The fall in MAP evoked by L-serine in all groups was 
accompanied by a marginal increase in HR but it failed to attain statistical significance in 
all groups (Table 4).  The estimated EC50 values for D-and L-serine were 1.4-2.3 and 0.8-
1.1 mmol/kg assuming the maximal effect occurred at 3.0 mmol/kg in all groups of 
animals.  Concentration higher than 3.0 mmol/kg was not infused since it was difficult to 
record the MAP to basal level.  D-and L-serine evoked a fall in MAP that was significantly 
reduced by pretreatment with apamin and ChTX in both normotensive and hypertensive rat 
models but the degree of inhibition to L-serine was relatively higher compared to D-serine 
in SHR strain (Figure 13 b and Figure 15).  Glycine is a metabolite or precursor of L-serine 
(Snell, 1984 and 1986).  When comparable doses of glycine were infused (0.3 to 3.0 
mmol/kg), it evoked a fall in MAP with no significant increase in HR in normotensive 
Sprague-Dawley and WKY strains.  However, the degree of fall in MAP attained with 
glycine was relatively lower than the responses attained with comparable doses of L-serine 
(Figure 16 and Table 4).  Glycine evoked a fall in MAP that was abolished by pretreatment 
with NMDA receptor selective antagonist, MK-801 (75 mg/kg). Pretreatment with MK-801 
did not affect the basal as well as L-serine evoked fall in MAP (Figure 16).  Paradoxically, 
and unlike L-serine, glycine evoked dose-dependent pressor responses in both SHR and L-
NAME treated rats (Figure 17 a and b left panel).  The maximal pressor responses to 
glycine attained at 3.0 mmol/kg (29 ± 3 mmHg, p < 0.01) and (39 ± 5 mmHg, p < 0.01) in 
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SHR and L-NAME treated rats.  Pretreatment with MK-801 a selective NMDA receptor 
antagonist, abolished the pressor response induced by glycine in both L-NAME pretreated 
WKY and SHR strains.  It was confirmed that MK-801 did not affect the responses to L-
serine (Figure 17 a and b, right panel).  Glycine evoked a fall in MAP in normotensive 
WKY rats and elevation in MAP in both the hypertensive rat models.  These responses 
blocked after pretreatment with NMDA receptor selective antagonist MK-801 are 
graphically represented (Figure 18). The data from a representative experiment 
demonstrates the hypotensive response to glycine in normotensive rats as well as the 
pressor response in hypertensive rats including the selective blockade of either response to 
glycine by NMDA antagonist, MK-801 (Figure 18).  In order to ensure that an acute 
elevation in MAP following L-NAME (100 mg/kg) administration did not contribute to the 
exaggerated pressor response to glycine, experiments were performed in normotensive 
WKY rats.  Glycine infusion evoked a dose dependent fall in MAP in this group of rats. 
Glycine neither elevated nor reduced MAP in this group of rats following acute intravenous 
administration of L-NAME, where as L-serine still produced a dose dependent fall in MAP 
(Figure 19).  Comparable doses of L-threonine, a precursor of L-serine, had no effect on 
MAP in normotensive and hypertensive rat models (Figure 20).  The dose dependent 
responses to all the amino acids were reproducible irrespective of the order in which they 
were infused in all the strains.  
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Table 4.  Comparison of mean arterial pressure (MAP, mmHg) and heart rate (HR, beats per 
minute) recorded continuously before and after infusion of either L-serine or glycine (2 to 3 
mmol/kg) in 12 to14 week old male Sprague-Dawley, L-NAME pretreated Sprague-Dawley, 
Wistar Kyoto (WKY), L-NAME pretreated WKY and spontaneously hypertensive (SHR) rats. 
 
383 ± 8198 ± 5 †443 ± 1088 ± 4 ††401 ± 8169 ± 4 **SHR
354 ± 13183 ± 4 †427 ± 1152 ± 3 ††377 ± 12149 ± 4 **Wistar-kyoto
(L-NAME Treated)
399 ± 989 ± 2 †410 ± 869 ± 4 †381 ± 10114 ± 3Wistar-Kyoto
(Control)
321 ± 7180 ± 5 †391 ± 947 ± 4 ††343 ± 8142 ± 3 *Sprague-Dawley
(L-NAME Treated)
381 ± 1291 ± 3386 ± 1083 ± 5 †364 ± 11111 ± 4Sprague-Dawley
(Control)
HRMAPHRMAPHRMAP
GlycineL-SerineBaselineStrain
 
 
Each data point is mean ± SEM of n = 5 to 7 rats per group. 
*p < 0.05 vs. SD (control) group; **p < 0.01 vs. WKY (control) group; †p < 0.05; ††p < 
0.01 vs. respective baseline value in the same group prior to infusion of either L-serine or 
glycine. 
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Figure 12.  A typical experiment compares MAP to acute comparable doses (0.3 to 3.0 
mmol/kg) of D-serine followed by L-serine (a) infusion in a 14 week old male 
normotensive Wistar-Kyoto [WKY (control)] rat.  The bottom panels (b) show the changes 
in MAP to D-serine followed by L-Serine infusion (0.3 to 2.0 mmol/kg) in a hypertensive 
WKY [WKY (L-NAME)] rat subjected to chronic nitric oxide synthase (NOS) inhibition 
by pretreatment with L-NAME (0.7 mg/ml in drinking water) for 5 days.  The maximal 
dose of D- or L- serine used was limited to 2.0 mmol/kg due to protracted hypotension at 
higher doses, when it was infused in L-NAME treated rats. Similar response patterns were 
seen for D- and L-serine in 6 WKY (control) and L-NAME treated WKY rats.  The 
response patterns to both isomers were also comparable to that of WKY control group in 12 
to 14 week old male Sprague-Dawley rats (n = 5 to 7 rats).   
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Figure 13. This is a typical experiment that compares MAP to acute i.v. infusion of 
increasing doses (0.3 to 3.0 mmol/kg) of D-Serine followed by L-serine in a 14 week old 
male SHR in the upper panel (a).  The lower panel (b) depicts the responses to similar doses 
of D-serine followed by L-Serine infused in the same animal after pretreatment with 
apamin and charybdotoxin combination (75 µg/kg of each given i.v. by slow infusion over 
a 15 min period).  Similar results were obtained in 6 age-matched male SHR.  
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Figure 14.  Dose response curves comparing mean arterial pressure (MAP) evoked by D-
serine ({) and L-serine (●) in 14 week old male normotensive Sprague-Dawley (a) or 
WKY (b) vs. hypertensive WKY that received L-NAME (0.7mg/ml in drinking water for 
five days) treatment (c) or SHR (d) strains.  Each data point represents mean ± SEM (n = 5 
to 7 rats/group). *p < 0.05 and **p < 0.01 vs. data point for D-serine dose in the same 
group.  †p < 0.05 and ††p < 0.01 vs. data for basal MAP prior to infusion of D- or L-serine 
in the same group.  The maximal dose of D- or L- serine used was limited to 2 mmol/kg 
due to protracted hypotension at higher doses, when it was infused in L-NAME treated rats. 
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Figure 15.  Each bar represents mean ± SEM maximum fall in MAP determined in 5 to 7 
rats for each group. *p < 0.05, **p < 0.01 vs. data for D-serine (D-S) in the same strain.  †p 
< 0.05 and ††p < 0.01 vs. respective data for D-S or L-serine (L-S) values prior to slow 
infusion of a combination of apamin + charybdotoxin (75 µg/kg, i.v.) in the same group. 
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Figure 16.  A typical experiment shows the fall in MAP evoked by increasing doses (0.3 to 
3.0 mmol/kg, i.v.) of glycine before and 30 minutes after the infusion of NMDA selective 
antagonist, MK-801 (75 mg/kg, i.p.), given over a period of 15 minutes.  MK-801 blocked 
the responses to glycine but not to L-serine.  The time scale on the X-axis is reduced for the 
right hand side panel MK-801 treatment as the data was compressed to accommodate data 
for glycine followed by responses to L-serine (a total of 9 responses).  Similar results were 
reproduced in seven age-matched male normotensive Sprague-Dawley and WKY rats.  
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Figure 17.  A typical experiment compares MAP with increasing doses of glycine (0.3 to 
3.0 mmol/kg, i.v.) infusion in L-NAME treated WKY rat (a) before (left upper panel) and 
after (right upper panel) the administration of NMDA antagonist, MK-801.  The pressor 
responses to glycine were absent after MK-801 treatment, but the response to L-Serine 
persisted.  The lower panel (b) shows the pressor responses to increasing doses of glycine 
infusion and the lack of pressor responses to the same doses of glycine infusion after the 
administration of MK-801.  
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Figure 18.  The dose-response relationships for glycine evoked changes in MAP either 
before ({) and after MK-801 (●) infusion in WKY (a), L-NAME pretreated hypertensive 
WKY (b) or SHR (c) strains.  Each data point is mean ± SEM (n = 5 to 7 rats/group).  *p < 
0.05 and **p < 0.01 vs. data of basal MAP prior to infusion of glycine in each group.  
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Figure 19.  A typical experiment compares MAP to increasing doses of glycine (0.3 to 3.0 
mmol/kg, i.v.) before (left hand panel) and the lack of responses to the same doses of 
glycine 1 hour after L-NAME (100 mg/kg, i.v.) infusion in a normotensive WKY rat. While 
glycine responses were blunted L-serine responses persisted following acute L-NAME 
infusion.  The X-axis time scale was compressed for the right hand side panel to 
accommodate 8 responses.  Similar data were reproduced in 5 WKY rats.  
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Figure 20. A representative experiment depicts that infusion of L-threonine (0.3 to 3.0 
mmol/kg) failed to alter MAP recording in a normotensive WKY rat (a) and chronic L-
NAME treated hypertensive WKY rat (b) and a SHR (c) strain.  These results were 
reproduced in 5 to 7 different rats from each group.  
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4.2.3. Regional Hemodynamic Study 
 
4.2.3.1. Comparison of Basal Regional Blood Flow 
 We observed significant reductions in basal blood flow to several organs in 
hypertensive rat models compared to normotensive rats.  A subtle difference exists in basal 
flow to different organs between L-NAME pretreated hypertensive WKY and SHR strains.   
 
4.2.3.1.1. Normotensive vs. Hypertensive Rat Models 
 We compared the basal regional blood flow to 13 different organs/tissues after 
vehicle (physiological saline) infusion (0.4 ml/kg) in normotensive WKY, L-NAME 
pretreated hypertensive WKY and SHR strains.  Basal blood flow to left and right kidney 
was found to be similar with a variation that was <5% in the respective normotensive or 
hypertensive rats.  A significant difference in blood flow was observed in both L-NAME 
pretreated hypertensive WKY and SHR strains compared to normotensive WKY rats.  In 
normotensive WKY rats, kidney received the highest blood flow (5.4 to 6.0 ml/min/g) 
followed by heart (3.4 to 3.7 ml/min/g).  Except liver, all other organs received blood flow 
between 1.0 to 1.5 ml/min/kg (Table 5, Figure 22, 23 and 24).  On the other hand in chronic 
L-NAME treated WKY rats, a decrease in blood flow occurred in most organs studied 
except brain and the heart.  The decrease in blood flow to spleen was significant (p < 0.01) 
followed by small intestine and kidney (p < 0.05) compared to what was observed in 
normotensive control rats (Table 5, Figure 22, 23 and 24).  In SHR strain, there was a 
decrease in blood flow to most organs studied compared to normotensive control WKY 
rats.  The decrease in blood flow was noted in spleen and kidney (p < 0.01), pancreas, small 
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and large intestine (p < 0.05) while blood flow values were not significantly lower in the 
brain and heart compared to the values noted in their normotensive strains (Table 5, Figure 
22, 23 and 24).  In SHR strain there was a significant increase in blood flow to heart (p < 
0.01) and brain (p < 0.05) compared to normotensive control strain of WKY rats (Table 5, 
Figure 22, 23 and 24). 
 
4.2.3.1.2. L-NAME Pretreated Hypertensive WKY vs. SHR  
 In SHR strain, there was an increase in blood flow to heart (p < 0.01) and a decrease 
in blood flow to kidney (p < 0.05) compared to the response noted in L-NAME pretreated 
hypertensive rats.  On the other hand, there is an overall decrease in blood flow in all other 
organs studied in SHR compared to L-NAME pretreated hypertensive WKY rats (Table 5, 
Figure 22, 23 and 24). 
 
4.2.3.2. Acetylcholine Induced Changes in Regional Blood Flow 
 ACh is a well known endothelium-dependent vasodilator that promotes a rapid, 
reversible, but robust dose-dependent fall in MAP both in normotensive and hypertensive 
rats (Desai et al., 2006).  L-serine is also an endothelium-dependent vasodilator and it 
decreases MAP in normotensive and hypertensive rat models but L-serine is less potent 
compared to ACh.  Therefore it was necessary to examine ACh-evoked increases in blood 
flow to different organs as a known reference sample, as a positive control for appropriate 
comparison to L-serine.  A submaximal dose of ACh (10 nmol/kg) increased blood flow 
significantly only to heart and kidney (p < 0.05) compared to vehicle infusion in the same 
group of animals.  ACh infusion increased the blood flow to all organ studied but the 
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increase observed did not attain statistical significance (Table 6 and Figure 21).  Moreover 
the sequence of vehicle and ACh infusion did not alter the selective and significant in 
crease in blood flow to heart and kidney evoked by ACh infusion in all strains. 
 
4.2.3.3. L-serine Induced Changes in Regional Blood Flow 
  
4.2.3.3.1. Normotensive Control WKY vs. Hypertensive Rat Models 
 L-serine induced increase in blood flow in normotensive control WKY, L-NAME 
pretreated WKY and SHR stains.  In normotensive WKY group L-serine (1 mmol/kg) 
infusion increase in blood flow was significant in small intestine and heart (74% and 39%, 
p < 0.05) compared to vehicle infusion (Table 10, Figure 22, 23 and 24).  In L-NAME 
treated hypertensive WKY rats, L-serine induced increase in blood flow was significant in 
most organ studied compared to vehicle infusion in the same group.  It followed the 
following rank order small intestine (392%, p < 0.001, Table 11), spleen, diaphragm, and 
heart (155%, 111%, and 65%, p < 0.01, Table 11), liver, large intestine and kidney (103%, 
85% and 30%, p < 0.05, Table 11).  The increase in blood flow evoked by L-serine was 
much less in stomach (12%), lungs (11%), pancreas (7%) and brain (3%), (Figure 22, 23, 
and 24, Table 11).  In SHR group there was an increase in blood flow occurring in brain 
and heart prior to infusion of L-serine (Table 5).  After L-serine infusion, a significant 
increase in blood flow was noted in small intestine (265%), spleen (177%) and kidney 
(82%), liver (160%), diaphragm (143%), large intestine (124%), pancreas (121%), brain 
(27%) and heart (21%).  The increase in blood flow evoked by L-serine infusion was 
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minimal in the case of lungs and stomach and it was not significant compared to vehicle 
infusion in the same group of rats (Figure 22, 23 and 24, Table 5 and Table 12).  
 
4.2.3.3.2. L-NAME Pretreated Hypertensive WKY vs. SHR 
 In L-NAME pretreated WKY rats, L-serine induced increase in blood flow was 
significantly higher in small intestine and heart (p < 0.05) compared to SHR stains.  There 
was no statistical difference in all other organ studied between these two hypertensive rat 
models (Table 5, Figure 22, 23 and 24).  
 
4.2.3.4. Comparison of Basal Peripheral Vascular Resistance 
  
4.2.3.4.1. Normotensive WKY vs. Hypertensive Rat Models 
 A wide spread increase in organ vascular resistance in both L-NAME treated 
hypertensive WKY and SHR rats was noted (Table 7).  Data from several experiment 
revealed that increase in vascular resistance was more pronounced in SHR compared to L-
NAME induced hypertensive rats (Table 7).  In L-NAME treated rats, peripheral vascular 
resistance significantly increased in spleen, small intestine, large intestine (p < 0.01), 
kidney, liver, stomach, lungs, pancreas and diaphragm (p < 0.05) compared to the 
peripheral vascular resistance seen in the normotensive control WKY rats receiving vehicle 
infusion except heart and brain (Table 7, Figure 25, 26, and 27).  In the SHR group, 
peripheral organ vascular resistance increased significantly in most organs studied such as  
large intestine, spleen, kidney, pancreas, small intestine, stomach, liver, lungs and 
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diaphragm (p < 0.01) compared to the peripheral vascular resistance encountered in 
normotensive control rats receiving vehicle infusion (Table 7, Figure 25, 26 and 27).    
 
4.2.3.4.2. L-NAME Pretreated Hypertensive WKY vs. SHR 
 In the SHR group, basal peripheral vascular resistance was significantly higher in 
most organs studied in comparison to L-NAME pretreated hypertensive WKY rats.  The 
following rank order of response was noted: pancreas (p < 0.01), kidney, liver, spleen, 
brain, lungs, stomach, small intestine, large intestine and diaphragm (p < 0.05) while it was 
negligible or absent in heart (Table 7, Figure 25, 26, and 27).  
 
4.2.3.5. L-serine Induced Changes in Peripheral Vascular Resistance 
  L-serine infusion reduced organ vascular resistance in both normotensive and 
hypertensive rat models.  L-serine evoked decrease in organ vascular resistance occurred in 
multiple organs in both hypertensive models (L-NAME treated and SHR) compared to 
normotensive WKY rats.  
 
4.2.3.5.1. Normotensive Control WKY vs. Hypertensive Rats 
 L-serine infusion in normotensive control WKY rat produced a significant decrease 
in peripheral vascular resistance only in small intestine compared to vehicle infusion given 
in same group of rats (42%, p < 0.05, Table 13).  In L-NAME pretreated hypertensive rats, 
L-serine infusion significantly reduced the peripheral vascular resistance in small intestine, 
spleen and liver (79%, 61% and 51%, p < 0.001), diaphragm and large intestine (52% and 
46%, p < 0.01, Table 14), heart and kidney (40% and 24%, p < 0.05) compared to vehicle 
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infusion in same group of rats (Table 14).  Decrease in the organ vascular resistance after 
L-serine infusion in lungs (11%), stomach (10%), pancreas (7%), brain (3%) and did not 
attain statistical significance compared to vehicle infusion in same group of rats (Table 14, 
Figure 25, 26 and 27).  Pooled data from several experiment showed that in L-NAME 
pretreated hypertensive rats the profound reduction in vascular resistance was observed in 
small intestine, spleen and liver after acute L-serine infusion.  This reduction in vascular 
resistance was even lower compared to vehicle infusion in the normotensive WKY rats 
(Table 7, Figure 25, 26 and 27).  In SHR group, L-serine infusion reduced organ vascular 
resistance significantly in spleen (64%) and liver (61%) (p < 0.001, Table 15), diaphragm 
(58%), large intestine (55%) and pancreas (54%) (p < 0.01, Table 15), kidney (46%) (p < 
0.05, Table 15) compared to vehicle infusion in same animals.  However, the reduction in 
vascular resistance was either minimal or negligible in the heart (19%), brain (32%), lungs 
(19%) and stomach (Table 15, Figure 25, 26, and 27). 
 
4.2.3.5.2. L-NAME Pretreated Hypertensive WKY vs. SHR 
 L-serine infusion led to a decrease in peripheral vascular resistance in several 
organs of SHR and L-NAME treated hypertensive rats.  In L-NAME treated hypertensive 
WKY rats, L-serine infusion lowered vascular resistance in heart (p < 0.05, Table 7) but 
this was not the case in the SHR strain.  In contrast, it reduced vascular resistance in 
pancreas (p < 0.01, Table 7).  The reduction in vascular resistance attained was also 
significantly higher (p < 0.05) in small intestine after L-serine infusion in L-NAME 
pretreated rats compared to SHR strain (Table 7, Table 14 and Table 15).  
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4.2.3.6. Comparison of Basal Systemic Hemodynamics 
 Pooled data from several experiments showed that both MAP and TPR values were 
higher in L-NAME pretreated hypertensive WKY (142 ± 7 and 1.79 ± 0.02) and SHR 
strains (166 ± 6 and 1.96 ± 0.05) compared to normotensive WKY rats (108 ± 4 and 1.05 ± 
0.04).  In SHR strain, we found both MAP and CI were significantly higher (p < 0.05) 
compared to L-NAME pretreated hypertensive WKY rats (166 ± 6 vs. 142 ± 7 and 274 ± 5 
vs. 232 ± 6, Table 8).  HR was higher (p < 0.05) in SHR strains compared to L-NAME 
pretreated hypertensive WKY and normotensive WKY rats (398 ± 12 vs. 368 ± 11 and 357 
± 8, Table 8).  There was a significant decrease in CO both in L-NAME pretreated 
hypertensive WKY and SHR (79 ± 5, 84 ± 4 vs. 103 ± 3, p < 0.05) compared to 
normotensive control WKY rats (Table 8).  
  
4.2.3.6.1. L-serine Evoked Changes in Systemic Hemodynamics 
  
4.2.3.6.1.1. Normotensive Control WKY Rats 
 Acute L-serine infusion significantly reduced MAP, TPR and TPRI (22%, 24% and 
26%, p < 0.05, Table 16), and increased CO (11%, p < 0.05, Table 16) compared to vehicle 
infusion in WKY rats (Table 8 and Table 16).  The changes in HR (6%), CI (7%) after L-
serine infusion did not attain statistical significance compared to vehicle infusion in WKY 
rats (Table 8 and Table 16).    
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4.2.3.6.1.2. L-NAME Pretreated Hypertensive WKY Rats 
 In L-NAME treated hypertensive WKY rats, acute L-serine infusion significantly 
decreased MAP, TPR and TPRI (46%, 68% and 67%, p < 0.001, Table 17) and increased 
CO and CI (75% and 70%, P < 0.001, Table 17) compared to vehicle infusion in the same 
group of rats.  The increase in HR (7%) evoked by L-serine infusion did not attain 
statistical significance compared to vehicle infusion in the same group (Table 8 and Table 
17).  
 
4.2.3.6.1.3. SHR 
 In SHR strain acute L-serine infusion significantly reduced the MAP, TPR and 
TPRI (34%, 53% and 48%, p < 0.01, Table 18) and increased in CO and CI (41% and 42%, 
p < 0.01, Table 18) compared to vehicle infusion in the same group of rats.  The increase in 
HR (8%) after L-serine infusion did not attain statistical significance compared to vehicle 
infusion in the same group of rats (Table 8 and Table 18).  
 
4.2.3.6.1.4. Comparison in L-NAME Pretreated Hypertensive Rats and SHR 
 The basal MAP and TPR values observed were significantly higher (p < 0.05) in 
SHR strain (166 ± 6 mmHg, 1.96 ± 0.05 mmHg/ml/min) compared to level encountered in 
L-NAME treated rats (142 ± 7 mmHg, 1.79 ± 0.02 mmHg/ml/min, Table 8).  However the 
reduction in there systemic hemodynamic parameters following L-serine infusion was 
significantly higher (p < 0.05) in L-NAME treated hypertensive rats (MAP: 46%, TPR: 
68%, p < 0.001, Table 17) in comparison to SHR strains (MAP: 34% and TPR: 53%, p < 
0.01, Table 18).  Moreover the level of increase in CO and CI was higher (p < 0.05) in L-
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NAME pretreated hypertensive WKY rats (CO: 75% and CI: 70%, Table 17) than what 
was noted in SHR groups (CO: 41% and CI: 42%, Table 18).  The increase in HR in both 
L-NAME treated hypertensive WKY rats (8%) and SHR groups (7%) did not attain 
statistical significance (Table 8, Table 17 and Table 18).  
 
4.2.3.7. Effect of L-serine in Presence of Apamin and Charybdotoxin 
 Pretreatment with apamin and ChTX for 45 min, significantly attenuated the 
increase in blood flow to small intestine in normotensive control WKY rats and several 
organs of L-NAME treated hypertensive rats and SHR groups (Table 9, Table 19, Table 20, 
Table 21, Figure 28, 29, 30, 31 and 32).  
 
4.2.3.7.1. Normotensive Control WKY Rats 
 Pretreatment with apamin and ChTX for 45 min significantly reduced the L-serine 
induced increase in blood flow to small intestine (p < 0.05) in normotensive WKY 
compared to the values obtained after L-serine infusion in the same group of rats (Table 9, 
Table 19, and Figure 30).  
 
4.2.3.7.2. L-NAME Pretreated Hypertensive WKY Rats 
 L-serine induced increases in blood flow to small intestine, large intestine, heart, 
both left and right kidney, spleen, skeletal muscle and diaphragm were significantly 
reduced (p < 0.01) by pretreatment with apamin and ChTX combination while blood flow 
to liver, brain, spleen, lungs, stomach and pancreas were not reduced to a significant extent. 
(Table 9, Table 20, Figure 28, 29, 30, 31 and 32). 
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4.2.3.7.3. SHR 
 Pretreatment with apamin and ChTX combination significantly reduced (p < 0.05) 
the increase in blood flow induced by L-serine to small intestine, spleen, the kidneys, large 
intestine, skeletal muscle, and diaphragm in SHR.  While blood flow to heart, liver, 
stomach, lungs, pancreas and brain were not reduced to a significant extent (Table 9, Table 
21, Figure 28, 29, 30, 31 and 32).   
 
4.2.3.7.4. Comparison between L-NAME Pretreated Hypertensive Rats and SHR 
 In L-NAME treated hypertensive rats, pretreatment with apamin and ChTX 
combination was significantly reduced the increase in blood flow to L-serine in small 
intestine (p < 0.01) and heart, spleen, diaphragm and skeletal muscle (p < 0.05).  While in 
SHR group, pretreatment with apamin and ChTX combination was significantly reduced (p 
< 0.05) the increase in blood flow to L-serine in spleen, small intestine, lungs, large 
intestine and diaphragm (Table 9, Table 20, Table 21, Figure 28, 29, 30, 31 and 32).  
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Figure 21.  Regional blood flow in heart, kidney and liver of 14 weeks old male 
normotensive Wistar-Kyoto (WKY) rats, L-NAME-induced hypertensive WKY [WKY (L-
NA)] rats and spontaneously hypertensive rats (SHR) following a single intravenous bolus 
dose of vehicle (saline, 0. 4ml/kg) followed by acetylcholine (ACh, 10 nmol/kg) infusion.  
Each bar is a mean ± SEM of 5 to 7 rats.  *p < 0.05 compared to vehicle treatment in the 
same group.  †p < 0.05 and ††p < 0.01 compared to normotensive control WKY group. 
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Figure 22.  Changes in regional blood flow to heart, left kidney, right kidney and liver 
following a single bolus dose of vehicle followed by L-serine (1 mmol/kg, i.v.) in 14 week 
old male WKY rats, L-NAME pretreated hypertensive WKY [WKY (L-NA)] rats and SHR 
strains.  Each bar is a mean ± SEM of 5 to 7 rats.  *p < 0.05 and **p < 0.01 compared to 
vehicle treatment in the same group.  †p < 0.05 and ††p < 0.01 compared to normotensive 
control WKY group. 
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Figure 23.  Changes in regional blood flow to spleen, brain, lungs and stomach following a 
single bolus dose of vehicle followed by L-serine (1 mmol/kg, i.v.) in 14 week old male 
WKY rats, L-NAME pretreated hypertensive WKY [WKY (L-NA)] rats and SHR strains.  
Each bar is a mean ± SEM of 5-7 rats.  *p < 0.05 and **p < 0.01 compared to vehicle 
treatment in the same group.  †p < 0.05 and ††p < 0.01 compared to normotensive control 
WKY group. 
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Figure 24.  Changes in regional blood flow to small intestine, large intestine, diaphragm 
and pancreas following a single bolus dose of vehicle followed by L-Serine (1 mmol/kg, i.v.) 
in 14 week old male WKY rats, L-NAME pretreated hypertensive WKY [WKY (L-NA)] 
rats and SHR strains.  Each bar is a mean ± SEM of 5-7 rats.  *p < 0.05, **p < 0.01 and 
***p < 0.001 compared to vehicle treatment in the same group.  †p < 0.05 compared to 
normotensive control WKY group. 
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Figure 25.  Changes in peripheral vascular resistance following a single bolus dose of 
vehicle followed by L-serine (1 mmol/kg, i.v.) in heart, left kidney, right kidney and liver 
of 14 week old male WKY rats, L-NAME pretreated hypertensive WKY [WKY (L-NA)] 
rats and SHR strains.  Each bar is a mean ± SEM of 5 to 7 rats.  *p < 0.05 and ***p < 0.001 
compared to vehicle treatment in the same group.  †p < 0.05 and ††p < 0.01 compared to 
normotensive control WKY group. 
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Figure 26. Changes in peripheral vascular resistance following a single bolus dose of 
vehicle followed by L-serine (1 mmol/kg, i.v.) in spleen, brain, lungs and stomach of 14 
week old male WKY rats, L-NAME pretreated hypertensive WKY [WKY (L-NA)] rats and 
SHR strains.  Each bar is a mean ± SEM of 5 to 7 rats.  ***p < 0.001 compared to vehicle 
treatment in the same group.  †p < 0.05 and ††p < 0.01 compared to normotensive control 
WKY group. 
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Figure 27.  Peripheral vascular resistance following a single bolus dose of intravenous 
infusion of vehicle followed by L-serine (1 mmol/kg)in small intestine, large intestine, 
diaphragm and pancreas of 14 week old male WKY rats, L-NAME pretreated hypertensive 
WKY [WKY (L-NA)] rats and SHR strains.  Each bar is a mean ± SEM of 5 to 7 rats.  *p < 
0.05, **p < 0.01 and ***p < 0.001 compared to vehicle treatment in the same group.  †p < 
0.05 and ††p < 0.01 compared to normotensive control WKY group. 
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Figure 28. Changes in regional blood flow following acute infusion of vehicle, L-serine 
and followed by L-serine (1 mmol/kg, i.v.) in presence of apamin and charybdotoxin (75 
μg/kg) in heart, left and right kidney of 14 week old male WKY, L-NAME pretreated 
hypertensive WKY [WKY (L-NA)] rats and SHR strains.  Each bar is a mean ± SEM of 2 
to 3 rats.  *p < 0.05 and **p < 0.01 compared to vehicle treatment in the same group                       
and †p < 0.05 compared to L-serine treatment in the same group. 
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Figure 29. Changes in regional blood flow following acute infusion of vehicle, L-serine 
and followed by L-serine (1 mmol/kg, i.v.) in presence of apamin and charybdotoxin (75 
μg/kg) in liver, spleen and brain of 14 week old male WKY, L-NAME pretreated 
hypertensive WKY [WKY (L-NA)] rats and SHR strains.  *p < 0.05 and **p < 0.01 
compared to vehicle treatment in the same group and †p < 0.05 compared to L-serine 
treatment in the same group. 
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Figure 30. Changes in regional blood flow following acute infusion of vehicle, L-serine 
and followed by L-serine (1 mmol/kg, i.v.) in presence of apamin and charybdotoxin (75 
μg/kg) in lungs, stomach and small intestine of 14 week old male WKY, L-NAME 
pretreated hypertensive WKY [WKY (L-NA)] rats and SHR strains.  *p < 0.05, **p < 0.01 
and ***p < 0.01 compared to vehicle treatment in the same group and †p < 0.05 and ††p < 
0.01 compared to L-serine treatment in the same group. 
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Figure 31. Changes in regional blood flow following acute infusion of vehicle, L-serine 
and followed by L-serine (1 mmol/kg, i.v.) in presence of apamin and charybdotoxin (75 
μg/kg) in large intestine and pancreas of 14 week old male WKY, L-NAME pretreated 
hypertensive WKY [WKY (L-NA)] rats and SHR strains.  *p < 0.05 and **p < 0.01 
compared to vehicle treatment in the same group and †p < 0.05 compared to L-serine 
treatment in the same group. 
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Figure 32. Changes in regional blood flow following acute infusion of vehicle, L-serine 
and followed by L-serine (1 mmol/kg, i.v.) in presence of apamin and charybdotoxin (75 
μg/kg) in diaphragm and skeletal muscle of 14 week old male WKY, L-NAME pretreated 
hypertensive WKY [WKY (L-NA)] rats and SHR strains.  *p < 0.05 and **p < 0.01 
compared to vehicle treatment in the same group and †p < 0.05 compared to L-serine 
treatment in the same group. 
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Table 5. Changes in regional blood flow (ml/min/g) in different organs/tissues after acute 
infusion of L-serine (1 mmol/kg, i.v.) in 14 week old male normotensive WKY, L-NAME 
pretreated WKY (0.7 mg/ml L-NAME in drinking water for 5 to 7 days) and SHR strains. 
 
Regional blood flow (ml/min/g) 
WKY (Control)  
 
WKY 
(L-NAME treated) 
 
SHR 
 
Tissues 
(Vehicle) ( L-serine) (Vehicle) ( L-serine) (Vehicle) (L-serine) 
Heart 3.58 ±0.13 4.99±0.07* 4.23±0.05 6.99±0.12** 5.35±0.14†† 6.47±0.19* 
L. kidney 5.60±0.22 6.22±0.20 3.97±0.14† 5.16±0.18* 2.89±0.20†† 5.21±0.19** 
R. kidney 5.81±0.19 6.59±0.28 4.13±0.15† 5.29±0.20* 2.99±0.13†† 5.45±0.18** 
Liver 0.42±0.06 0.48±0.07 0.34±0.06 0.69±0.08* 0.30±0.05 0.78±0.07* 
Spleen 1.45±0.13 1.86±0.25 0.78±0.10†† 1.99±0.12** 0.69±0.11†† 1.91±0.18** 
Brain 0.98±0.08 0.94±0.09 1.09±0.12 1.12±0.13 1.38±0.14† 1.75±0.15* 
Lungs 0.88±0.07 0.96±0.06 0.72±0.12 0.80±0.11 0.64±0.12 0.80±0.16 
Stomach 0.95±0.14 0.89±0.12 0.76±0.15 0.85±0.18 0.62±0.13 0.72±0.17 
S. intestine 1.35±0.18 2.35±0.17* 0.79±0.09† 3.89±0.15*** 0.84±0.15† 2.89±0.32** 
L. intestine 1.40±0.22 1.51±0.24 0.88±0.11 1.63±0.28* 0.66±0.10† 1.48±0.23* 
Diaphragm 1.42±0.25 1.89±0.28 1.41±0.18 2.97±0.24** 1.14±0.15 2.78±0.26* 
Pancreas 1.19±0.19 1.22±0.19 0.97±0.16 1.04±0.18 0.63±0.12† 1.39±0.13* 
 
 
Data reported as mean ± SEM for 5 to 7 rats/group. 
*p < 0.05, **p < 0.01 and ***p < 0.001 compared to respective control group. 
†p < 0.05 and ††p < 0.01 compared to control group. 
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Table 6. Changes in regional blood flow (ml/min/g) in different organs/tissues after acute 
infusion of ACh (10 nmol/kg, i.v.) in 14 week old male normotensive WKY, L-NAME 
pretreated WKY (0.7 mg/ml L-NAME in drinking water for 5 to 7 days) and SHR strains. 
 
Regional blood flow (ml/min/g) 
WKY (Control)  
 
WKY 
(L-NAME treated) 
 
SHR 
 
Tissues 
(Vehicle) (ACh) (Vehicle) 
 
(ACh) (Vehicle) (ACh) 
Heart 3.58±0.19 5.26±0.17* 
 
4.23±0.14† 4.71±0.16 5.35±0.28††  6.09±0.29 
L. kidney 5.60±0.35 7.38±0.33* 
 
3.97±0.13†  4.07±0.11 2.89±0.17††  2.99±0.18  
R. kidney 5.81±0.22 7.63±0.23* 
 
4.13±0.09† 4.24±0.11 2.99±0.16††  3.09±0.19  
Liver 0.42±0.11 0.55±0.12  
 
0.34±0.08  0.44±0.07 0.30±0.05  0.36±0.04  
Spleen 1.45±0.11 1.56±0.12  
 
0.82±0.14†  0.86±0.14 0.64±0.06††  0.77±0.05  
Brain 0.98±0.06  1.11±0.07  
 
1.09±0.12  1.18±0.11 1.38±0.13†  1.54±0.16  
Lungs 0.88±0.12  0.95±0.12  
 
0.72±0.07 0.81±0.08 0.64±0.09  0.74±0.13  
Stomach 0.95±0.13 0.91±0.12  
 
0.76±0.15  0.54±0.14 0.62±0.09  0.45±0.10  
S. intestine 1.35±0.14 1.44±0.11  
 
0.79±0.09† 0.87±0.09 0.84±0.10†  0.96±0.09  
L. intestine 1.41±0.10 1.49±0.11  
 
0.88±0.06†  0.93±0.068 0.66±0.06†  0.71±0.08  
Pancreas 1.19±0.11 1.22±0.08 
 
0.97±0.20  0.99±0.18 0.63±0.15†  0.68±0.11  
Diaphragm 1.42±0.16 1.45±0.08  
 
1.41±0.09  1.55±0.11 1.14±0.15 1.22±0.16 
Skeletal 
muscle 
0.15±0.02 0.22±0.03 0.11±0.02 0.13±0.04 0.22±0.05 0.27±0.07 
 
Data reported as mean ± SEM for 5 to 7 rats/group. 
*p < 0.05 compared to respective control group. 
†p < 0.05 and ††p < 0.01 compared to control group before ACh infusion. 
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Table 7. Acute L-serine (1 mmol/kg, i.v.) infusion reduced peripheral vascular resistance 
(mmHg/ml/min/g) in different organs/tissues in 14 week old male normotensive WKY, L-
NAME pretreated WKY (0.7 mg/ml L-NAME in drinking water for 5 to 7days) and SHR 
strains. 
 
Regional vascular resistance  (mm Hg/ml/min/g) 
WKY (Control)  
 
WKY 
(L-NAME treated) 
 
SHR 
 
Tissues 
(Vehicle) ( L-serine) (Vehicle) (L-serine) (Vehicle) (L-serine) 
Heart 30±4.4  22±4.0 35±4.4 21±3.4* 32±4.0 26±3.5 
L. kidney 20±2.5 17±2.4  37±2.6†  28±2.7 58±3.1††  32±3.0* 
R. kidney 19±1.4  16±1.4  35±3.3† 27±3.8 57±3.5††  31±3.5* 
Liver 256±16.7 220±15.9 426±16.4† 210±14.8*** 563±21.4†† 217±18.3***
Spleen 75±7.9 59±8.3  186±7.3†† 73±6.7*** 245±27.6†† 87±17.2*** 
Brain 112±6.4 117±6.1 134±21.2 130±19.9 143±16.9 97±16.8 
Lungs 125±14.5 
 
115±12.7 201±21.7† 179±22.2 263±24.9†† 211±22.1 
Stomach 116±10.2 
 
126±13.3 191±15.3† 171±15.0 272±27.4†† 234±23.2 
S. intestine 81±5.9 47±3.5*  184±10.3†† 38±5.4*** 199±17.6†† 68±16.3** 
L. intestine 77±9.4  72±10.2 165±12.6†† 89±14.1** 256±20.1†† 114±17.7** 
Diaphragm 76±8.7 59±8.4 102±7.8† 49±8.1** 148±12.2†† 61±16.0** 
Pancreas 93±8.5  90±12.3  149±14.8† 139±15.2 268±14.1†† 122±17.8** 
 
 
Data reported as mean ± SEM for 5 to 7 rats/group. 
*p < 0.05, **p < 0.01 and ***p < 0.001 compared to respective control group. 
†p < 0.05 and ††p < 0.01 compared to control group.  
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Table 8.  Comparison of systemic hemodynamic changes evoked by L-serine (1 mmol/kg, 
i.v.) in 14 week old WKY, L-NAME pretreated WKY (0.7 mg/ml L-NAME in drinking 
water for 5 to 7 days), and SHR strains. 
 
Group → WKY Control WKY  
(L-NAME treated)  
SHR 
Parameter Vehicle L-Serine Vehicle L-Serine Vehicle L-Serine 
MAP (mmHg) 108±4 84±5* 142±7†† 77±6*** 166±6†† 109±7** 
HR (beats/min) 357±3 381±9 368±11 391±10 398±12† 425±8 
CO (ml/min) 103±3 114±4* 79±5†† 138±4*** 84±4† 119±8** 
TPR 
(mmHg/ml/min) 
1.05±0.04 0.80±0.03* 1.79±0.02†† 0.58±0.04*** 1.96±0.05†† 0.93±0.05** 
CI (ml/min/kg) 309±7 331±9 232±6†† 394±7*** 274±5† 390±16** 
TPRI 
(mmHg/ml/min/kg) 
0.35±0.09 0.26±0.07* 
 
0.62±0.05† 0.20±0.07*** 
 
0.67±0.06† 0.35±0.06** 
 
 
Data reported as mean ± SEM for 5 to 7 rats/group. 
*p < 0.05, **p < 0.01 and ***p < 0.001 compared to respective control group. 
†p < 0.05 and ††p < 0.01 compared to control group. 
 
 
 
 
 
 
Table 9. L-serine (1 mmol/kg) induced increase in regional blood flow (ml/min/g) in different organs/tissues decreased in 
presence of apamin and charybdotoxin in normotensive WKY, L-NAME pretreated WKY (0.7 mg/ml L-NAME in drinking 
water for 5 to 7 days) and SHR strains 
Regional blood flow (ml/min/g) Tissues 
WKY 
(Control) 
(Vehicle) 
WKY 
(Control) 
(L-serine) 
WKY 
(Control) 
(L-s-
Apa+ChTX)
WKY 
(L-NAME) 
(Vehicle) 
WKY  
(L-NAME) 
(L-s) 
WKY  
(L-NAME) 
(L-s-
Apa+ChTX) 
SHR 
(Vehicle) 
SHR 
(L-s) 
SHR 
(L-s-
Apa+ChTX)
Heart 3.79±0.19 5.09±0.25* 4.38±0.24† 4.47±0.19 6.69±0.36* 5.12±0.29† 5.55±0.38 6.71±0.41 5.88±0.37 
L. kidney 5.32±0.31 5.88±0.29 5.66±0.31 3.55±0.14 4.75±0.25* 3.97±0.17 3.02±0.29 4.97±0.28* 4.04±0.31 
R. kidney 5.25±0.32 5.79±0.27 5.54±0.36 3.56±0.18 4.84±0.23* 3.89±0.21 2.96±0.20 5.02±0.34* 4.10±0.37 
Liver 0.55±0.05 0.64±0.07 0.59±0.03 0.48±0.03 0.79±0.09* 0.55±0.05 0.41±0.04 0.77±0.07* 0.61±0.07 
Spleen 1.3±0.10 1.63±0.11 1.47±0.17 0.62±0.06 1.76±0.18** 0.98±0.11† 0.59±0.07 1.78±0.21** 1.03±0.17† 
Brain 1.03±0.11 1.05±0.18 0.98±0.08 1.14±0.14 1.17±0.12 1.18±0.10 1.28±0.18 1.57±0.22 1.39±0.15 
Lungs 0.69±0.04 0.77±0.11 0.71±0.07 0.61±0.03 0.88±0.07 0.85±0.05 0.51±0.05 0.87±0.10* 0.63±0.07 
Stomach 1.01±0.14 1.21±0.11 1.16±0.18 0.80±0.15 0.93±0.17 0.86±0.16 0.78±0.06 0.95±0.11 0.84±0.09 
S. intestine 1.56±0.11 2.37±0.19* 1.68±0.13† 1.10±0.24 3.72±0.39** 2.12±0.28† 0.95±0.18 3.01±0.27** 1.97±0.21† 
L. intestine 1.35±0.34 1.64±0.28 1.42±0.17 0.99±0.11 1.67±0.18* 1.42±0.21 0.83±0.15 1.70±0.21* 1.18±0.17† 
Pancreas 1.04±0.09 1.21±0.16 1.11 ±0.12 0.89±0.14 1.10±0.21 1.04±0.19 0.67±0.08 1.31±0.17** 1.19±0.14 
Diaphragm 1.28±0.21 1.63±0.33 1.44±0.27 1.39±0.12 2.57±0.28** 1.65±0.14† 1.22±0.19 2.64±0.22** 1.77±0.17† 
Skeletal 
muscle 
0.19±0.05 0.23±0.08 0.21±0.07 0.09±0.03 0.17±0.05* 0.12±0.04 0.27±0.03 0.46±0.05* 0.35±0.04 
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Data reported as mean ± SEM for 3 to 4 rats/group. 
*p < 0.05, and **p < 0.01 compared to vehicle infusion in the same group. 
†p < 0.05 compared to L-serine treatment in the same group of rats. 
   
Table 10. Percentage increase or decrease in regional blood flow to acute L-serine (1 
mmol/kg, i.v.) infusion in 14 week old male normotensive control WKY rats. 
      
Regional blood flow (ml/min/g) Tissues 
WKY (Control) 
(Vehicle) 
 
WKY (Control) 
( L-serine) 
% (Increase) 
↑ 
Heart 3.58±0.13 4.99±0.07* 39 ↑ 
L. kidney 5.60±0.22 6.22±0.20  11 ↑ 
R. kidney 5.81±0.19 6.59±0.28 13 ↑ 
Liver 0.42±0.06  0.48±0.07  14 ↑ 
Spleen 1.45±0.13  1.86±0.25  28 ↑ 
Brain 0.98±0.08  0.94±0.09  - 4 ↓ 
Lungs 0.88±0.07  0.96±0.06   9  ↑ 
Stomach 0.95±0.14  0.89±0.12 - 6 ↓ 
S. intestine 1.35±0.18  2.35±0.17*   74 ↑ 
L. intestine 1.40±0.22  1.51±0.24   8  ↑ 
Diaphragm 1.42±0.25  1.89±0.28  33 ↑ 
Pancreas 1.19±0.19  1.22±0.19    3  ↑ 
 
Data reported as mean ± SEM for 5 to 7 rats/group. 
*p < 0.05 compared to vehicle treatment in the same group of rats. 
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Table 11.  Percentage increase or decrease in regional blood flow to acute L-serine (1 
mmol/kg, i.v.) infusion in 14 week old male L-NAME pretreated WKY rats (0.7 mg/ml L-
NAME in drinking water for 5 to 7 days).  
 
Regional blood flow (ml/min/g) Tissues 
WKY (L-NAME) 
(Vehicle) 
 
WKY (L-NAME)
( L-serine) 
% (Increase) 
↑ 
Heart 4.23±0.05  6.99±0.12**   65   ↑ 
L. kidney 3.97±0.14  5.16±0.18*  30   ↑  
R. kidney 4.13±0.15  5.29±0.20*    28   ↑ 
Liver 0.34±0.06  0.69±0.08*   103 ↑ 
Spleen 0.78±0.10  1.99±0.12**   155 ↑ 
Brain 1.09±0.12 1.12±0.13    3     ↑ 
Lungs 0.72±0.12  0.80±0.11  11   ↑ 
Stomach 0.76±0.15  0.85±0.18  12   ↑ 
S. intestine 0.79±0.09  3.89±0.15***  392 ↑ 
L. intestine 0.88±0.11  1.63±0.28*   85   ↑  
Diaphragm 1.41±0.18  2.97±0.24*    111 ↑ 
Pancreas 0.97±0.16  1.04±0.18   7     ↑ 
 
Data reported as mean ± SEM for 5 to 7 rats/group. 
*p < 0.05, **p < 0.01 and ***p < 0.001 compared to vehicle infusion in the same group. 
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Table 12. Percentage increase or decrease in regional blood flow to acute L-serine (1 
mmol/kg, i.v.) infusion in 14 week old male SHR strains. 
 
Regional blood flow (ml/min/g) Tissues 
SHR 
 (Vehicle) 
 
SHR 
( L-serine) 
% (Increase) 
↑ 
Heart 5.35±0.14 6.47±0.19*  21  ↑ 
L. kidney 2.89±0.20 5.21±0.19**  80  ↑ 
R. kidney 2.99±0.13 5.45±0.18**  82  ↑ 
Liver 0.30±0.05 0.78±0.07*  160 ↑ 
Spleen 0.69±0.11 1.91±0.18**  177 ↑ 
Brain 1.38±0.14 1.75±0.15*  27   ↑ 
Lungs 0.64±0.12 0.80±0.16  25   ↑ 
Stomach 0.62±0.13 0.72±0.17  16   ↑ 
S. intestine 0.84±0.15 2.89±0.32**  265 ↑ 
L. intestine 0.66±0.10 1.48±0.23*  124 ↑ 
Diaphragm 1.14±0.15 2.78±0.26*  143 ↑ 
Pancreas 0.63±0.12 1.39±0.13*  121 ↑ 
 
Data reported as mean ± SEM for 5 to 7 rats/group. 
*p < 0.05 and **p < 0.01 compared to vehicle infusion in the same group. 
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Table 13. Percentage decrease or increase in regional organ vascular resistance to acute L-
serine (1 mmol/kg, i.v.) infusion in 14 week old male normotensive control WKY rats. 
 
Regional vascular resistance  (mmHg/ml/min/g) Tissues 
WKY (Control) 
(Vehicle) 
 
WKY (Control) 
( L-serine) 
% (Decrease) 
↓ 
Heart 30±4.4  22±4.0 27 ↓ 
L. kidney 20±2.5 17±2.4  15 ↓ 
R. kidney 19±1.4  16±1.4  16 ↓ 
Liver 256±16.7 220±15.9 14 ↓ 
Spleen 75±7.9 59±8.3  21 ↓ 
Brain 112±6.4 117±6.1 -4 ↑ 
Lungs 125±14.5 115±12.7  8  ↓  
Stomach 116±10.2 126±13.3 -8  ↑  
S. intestine 81±5.9 47±3.5*  42 ↓  
L. intestine 77±9.4  72±10.2 6   ↓ 
Diaphragm 76±8.7 59±8.4 22 ↓ 
Pancreas 93±8.5  90±12.3  3   ↓ 
 
Data reported as mean ± SEM for 5 to 7 rats/group. 
*p < 0.05 compared to vehicle treatment in the same group of rats. 
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Table 14. Percentage decrease or increase in regional organ vascular resistance to acute L-
serine (1 mmol/kg, i.v.) infusion in 14 week old male L-NAME pretreated WKY rats (0.7 
mg/ml L-NAME in drinking water for 5 to 7 days). 
 
Regional vascular resistance  (mmHg/ml/min/g) Tissues 
WKY (L-NAME) 
(Vehicle) 
 
WKY (L-NAME)
( L-serine) 
% (Decrease) 
↓ 
Heart 35±4.4 21±3.4* 40 ↓ 
L. kidney 37±2.6  28±2.7 24 ↓ 
R. kidney 35±3.3 27±3.8 23 ↓ 
Liver 426±16.4 210±14.8*** 51 ↓ 
Spleen 186±7.3 73±6.7*** 61 ↓ 
Brain 134±21.2 130±19.9 3   ↓ 
Lungs 201±21.7 179±22.2 11 ↓ 
Stomach 191±15.3 171±15.0 10 ↓ 
S. intestine 184±10.3 38±5.4*** 79 ↓ 
L. intestine 165±12.6 89±14.1** 46 ↓ 
Diaphragm 102±7.8 49±8.1** 52 ↓ 
Pancreas 149±14.8 139±15.2 7   ↓ 
 
Data reported as mean ± SEM for 5 to 7 rats/group. 
*p < 0.05, **p < 0.01 and ***p < 0.001 compared to vehicle infusion in the same group. 
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Table 15. Percentage decrease or increase in regional organ vascular resistance to acute L-
serine (1 mmol/kg, i.v.) infusion in 14 week old male SHR strains. 
 
Regional vascular resistance  (mmHg/ml/min/g) Tissues 
SHR 
 (Vehicle) 
 
SHR 
( L-serine) 
% (Decrease) 
↓ 
Heart 32±4.0 26±3.5 19 ↓ 
L. kidney 58±3.1  32±3.0* 45 ↓ 
R. kidney 57±3.5  31±3.5* 46 ↓ 
Liver 563±21.4 217±18.3*** 61 ↓ 
Spleen 245±27.6 87±17.2*** 64 ↓ 
Brain 143±16.9 97±16.8 32 ↓ 
Lungs 263±24.9 211±22.1 19 ↓ 
Stomach 272±27.4 234±23.2 13 ↓ 
S. intestine 199±7.6 68±6.3** 70 ↓ 
L. intestine 256±20.1 114±17.7** 55 ↓ 
Diaphragm 148±12.2 61±16.0** 58 ↓ 
Pancreas 268±14.1 122±17.8** 54 ↓ 
 
Data reported as mean ± SEM for 5 to 7 rats/group. 
*p < 0.05, **p < 0.01 and ***p < 0.001 compared to vehicle infusion in the same group. 
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Table 16. Percentage changes in MAP (mmHg), HR (beats/min), CO (ml/min) and TPR 
(mmHg/ml/min), CI (ml/min/kg) and TPRI (mmHg/ml/min/kg) to L-serine (1 mmol/kg, 
i.v.) infusion in 14 week old normotensive control WKY rats. 
 
Group WKY (Control) 
Parameter Vehicle L-serine (% Decrease/Increase) 
↓↑ 
MAP (mmHg) 108±4 84±5* 22 ↓ 
HR (beats/min) 357±3 381±9 6   ↑ 
CO (ml/min) 103±3 114±4* 11 ↑ 
TPR (mmHg/ml/min) 1.05±0.04 0.80±0.03* 24 ↓ 
CI (ml/min/kg) 309±7 331±9 7   ↑ 
TPRI (mmHg/ml/min/kg) 0.35±0.09 0.26±0.07* 26 ↓ 
 
Data reported as mean ± SEM for 5 to 7 rats/group. 
*p < 0.05 compared to vehicle infusion in the same group. 
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Table 17. Percentage changes in MAP (mmHg), HR (beats/min), CO (ml/min), TPR 
(mmHg/ml/min), CI (ml/min/kg) and TPRI (mmHg/ml/min/kg) to L-serine (1 mmol/kg, 
i.v.) infusion in 14 week old male L-NAME pretreated WKY rats (0.7 mg/ml L-NAME in 
drinking water for 5 to 7 days). 
 
Group WKY (Chronic L-NAME) 
Parameter Vehicle L-serine (% Decrease/Increase) 
↓↑ 
MAP (mmHg) 142±7 77±6*** 46 ↓ 
HR (beats/min) 368±11 399±10 8   ↑ 
CO (ml/min) 79±5 138±4*** 75 ↑ 
TPR (mmHg/ml/min) 1.79±0.02 0.58±0.04*** 68 ↓ 
CI (ml/min/kg) 232±6 394±7*** 70 ↑ 
TPRI (mmHg/ml/min/kg) 0.62±0.05 0.20±0.07*** 67 ↓  
 
Data reported as mean ± SEM for 5 to 7 rats/group. 
***p < 0.001 compared to vehicle infusion in the same group. 
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Table 18. Percentage changes in MAP (mmHg), HR (beats/min), CO (ml/min), TPR 
(mmHg/ml/min), CI (ml/min/kg) and TPRI (mmHg/ml/min/kg) to L-serine (1 mmol/kg, 
i.v.) infusion in 14 week old male SHR strains. 
 
Group SHR 
Parameter Vehicle L-serine (% Decrease/Increase) 
↓↑ 
MAP (mmHg) 166±6 109±7** 34 ↓ 
HR (beats/min) 398±12 425±8  7  ↑ 
CO (ml/min) 84±4 119±8** 41 ↑ 
TPR (mmHg/ml/min) 1.96±0.05 0.93±0.05** 53 ↓ 
CI (ml/min/kg) 274±5 390±16** 42 ↑ 
TPRI (mmHg/ml/min/kg) 0.67±0.06 0.35±0.06** 48 ↓ 
 
Data reported as mean ± SEM for 5 to 7 rats/group. 
**p < 0.01 compared to vehicle infusion in the same group. 
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Table 19. Comparison of increase in regional blood flow to various tissues after acute L-
serine (1 mmol/kg, i.v.) infusion and L-serine infusion in presence of apamin and 
charybdotoxin in 14 week old male normotensive control WKY rats. 
 
Regional blood flow (ml/min/g) Tissues 
WKY Control 
(Vehicle) 
WKY Control 
(L-serine) 
% 
↑ 
WKY Control 
(L-serine-Apa+ChTX) 
 
% 
↑ 
Heart 3.79±0.19 
 
5.09±0.25* 34 4.38±0.24 16 
L. kidney 5.32±0.31 
 
5.88±0.29 11 5.66±0.31 6 
R. kidney 5.25±0.32 
 
5.79±0.27 10 5.54±0.36 6 
Liver 0.55±0.05 
 
0.64±0.07 16 0.59±0.03 7 
Spleen 1.31±0.10 
 
1.63±0.11 24 1.47±0.17 12 
Brain 1.03±0.11 
 
1.05±0.18 2 0.98±0.08 -5 
Lungs 0.69±0.04 
 
0.77±0.11 12 0.71±0.07 3 
Stomach 1.01±0.14 
 
1.21±0.11 20 1.16±0.18 15 
S. intestine 1.56±0.11 
 
2.37±0.19* 52 1.68±0.13† 8 
L. intestine 1.35±0.34 
 
1.64±0.28 21 1.42±0.17 5 
Pancreas  1.04±0.09 
 
1.21±0.16 16 1.11±0.12 7 
Diaphragm  1.28±0.21 
 
1.63±0.33 27 1.44±0.27 13 
Skeletal muscle 0.19±0.05 
 
0.23±0.08 21 0.21±0.07 11 
 
Data reported as mean ± SEM for 3 to 4 rats/group. 
*p < 0.05 compared to vehicle infusion in the same group. 
†p < 0.05 compared to L-serine treatment in the same group of rats. 
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Table 20. Comparison of increase in regional blood flow to various tissues after acute L-
serine (1 mmol/kg, i.v.) infusion and L-serine infusion in presence of apamin and 
charybdotoxin in 14 week old male L-NAME pretreated hypertensive WKY rats  (0.7 g/ml 
L-NAME in drinking water for 5 to 7days). 
 
Regional blood flow (ml/min/g) Tissues 
WKY (L-NAME) 
(Vehicle) 
WKY (L-NAME) 
(L-serine) 
% 
↑ 
WKY (L-NAME) 
(L-serine-Apa+ChTX) 
 
% 
↑ 
Heart 4.47±0.19 
 
6.69±0.36* 50 5.12±0.29† 15 
L. kidney 3.55±0.14 
 
4.75±0.25* 34 3.97±0.17 12 
R. kidney 3.56±0.18 
 
4.84±0.23* 36 3.89±0.21 9 
Liver 0.48±0.03 
 
0.79±0.09* 65 0.55±0.05 15 
Spleen 0.62±0.06 
 
1.76±0.18** 184 0.98±0.11† 58 
Brain 1.14±0.14 
 
1.17±0.12 3 1.18±0.10 4 
Lungs 0.61±0.03 
 
0.88±0.07 44 0.85±0.05 39 
Stomach 0.80±0.15 
 
0.93±0.17 16 0.86±0.16 6 
S. intestine 1.10±0.24 3.72±0.39** 238 2.12±0.28† 93 
L. intestine 0.99±0.11 1.67±0.18* 69 1.42±0.21 43 
Pancreas  0.89±0.14 
 
1.10±0.21 24 1.04±0.19 17 
Diaphragm  1.39±0.12 
 
2.57±0.28** 85 1.65±0.14† 19 
Skeletal muscle 0.09±0.03 
 
0.17±0.05* 77 0.12±0.04† 33 
 
Data reported as mean ± SEM for 3 to 4 rats/group. 
*p < 0.05, and **p < 0.01 compared to vehicle infusion in the same group. 
†p < 0.05 compared to L-serine treatment in the same group of rats. 
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Table 21. Comparison of increase in regional blood flow to various tissues after acute L-
serine (1 mmol/kg, i.v.) infusion and L-serine infusion in presence of apamin and 
charybdotoxin in 14 week old age matched male SHR. 
 
Regional blood flow (ml/min/g) Tissues 
SHR 
(Vehicle) 
SHR 
(L-serine) 
% 
↑ 
SHR 
(L-serine-Apa+ChTX) 
% 
↑ 
Heart 5.55±0.38 
 
6.71±0.41 21 5.88±0.37 6 
L. kidney 3.02±0.29 
 
4.97±0.28* 65 4.04±0.31 54 
R. kidney 2.96±0.20 
 
5.02±0.34* 69 4.10±0.37 55 
Liver 0.41±0.04 
 
0.77±0.07* 88 0.61±0.07 46 
Spleen 0.59±0.07 
 
1.78±0.21** 201 1.03±0.17† 88 
Brain 1.28±0.18 
 
1.57±0.22 23 1.39±0.15 9 
Lungs 0.51±0.05 
 
0.87±0.10* 71 0.63±0.07 24 
Stomach 0.78±0.06 
 
0.95±0.11 22 0.84±0.09 8 
S. intestine 0.95±0.18 
 
3.01±0.27** 216 1.97±0.21† 107 
L. intestine 0.83±0.15 
 
1.70±0.21* 105 1.18±0.17† 42 
Pancreas  0.67±0.08 
 
1.31±0.17** 96 1.19±0.14 78 
Diaphragm  1.22±0.19 
 
2.64±0.22** 99 1.77±0.17† 48 
Skeletal muscle 0.27±0.03 
 
0.46±0.05* 68 0.35±0.04 30 
 
Data reported as mean ± SEM for 2 to 3 rats/group. 
*p < 0.05 and **p < 0.01 compared to vehicle infusion in the same group. 
†p < 0.05 compared to L-serine treatment the same group of rats. 
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CHAPTER 5. DISCUSSION 
 
5.1. Vasodilator Properties of L-serine  
 The present study demonstrates the vasodilator effect of L-serine (10 to 200 
μmol/L) in rat mesenteric arteriole.  L-serine evoked vasodilator effect is more pronounced 
in NO compromised state.  L-serine evoked vasodilatation was concentration-dependent 
and it was observed only in endothelium-intact preparations.  The maximal vasodilator 
responses to L-serine was observed in mesenteric arteriole isolated from L-NAME 
pretreated hypertensive rats compared to normotensive control rats (40 ± 3% vs. 20 ± 3%).  
The vasodilator responses to L-serine were similar when vessels were preconstricted with 
PE, or the thromboxane analog, U46619.  The vasodilator responses to L-serine were 
insensitive to blockade by either NOS inhibitor, L-NAME, or the COX inhibitor, 
indomethacin.  Pretreatment with either a combination of apamin plus TRAM-34 or 
ouabain plus Ba2+ significantly blocked the vasodilator responses to L-serine in these 
arterioles.  L-serine mediated vasodilator effect was absent when mesenteric arterioles were 
depolarized with KCl (80 mmol/L).  In PE constricted mesenteric arterioles, addition of 
KCl (9.8 to 18.8 mmol/L) evoked a vasodilator responses, this effect was abolished in 
vessels pretreated with a combination of ouabain plus Ba2+ but not in the combine presence 
of apamin plus TRAM-34.  In this preparation, addition of L-serine failed to increase 
further the vasodilator responses to KCl.  From this data it is evident that, L-serine 
promotes K+ efflux by activating SKCa and IKCa channels present in the endothelium.  The 
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efflux of K+ from endothelium hyperpolarized the VSMC via activation of the Na+ pump 
and subsequent efflux of K+ through Kir channels.  
 
5.2. BP Lowering Effect of L-serine 
 Our in vitro observations were extended to explore the potential in vivo effects of L-
serine.  Acute L-serine infusion in normotensive and L-NAME pretreated hypertensive rats 
lowers BP with minimal increase in HR.  The BP lowering effect of L-serine was dose 
dependent and more pronounced in L-NAME pretreated hypertensive rats compared to 
normotensive control rats.  Pretreatment with combination of apamin (SKCa inhibitor) and 
ChTX (IKCa inhibitor) significantly abolished the BP lowering effect of L-serine (0.1 to 2.0 
mmol/kg).  L-serine infusion at 3.0 mmol/kg concentration elicited a profound fall in MAP 
which was >70 mmHg in L-NAME pretreated hypertensive rats and this effect was 
inhibited significantly but not completely blocked by apamin and ChTX. This effect 
suggests the involvement of additional mechanisms in reduction of MAP in L-NAME 
pretreated hypertensive rat models.  L-serine evoked a fall in BP that was insensitive to 
indomethacin and acute L-NAME pretreatment.  This observation confirms that the L-
serine evoked fall in BP was NO- and COX-independent.  Taken together all these data 
favor the conclusion that L-serine likely promotes selective activation of SKCa and IKCa 
channels present on the endothelium.  The fall in MAP observed was lower in 
normotensive control rats (Emax > 25 mmHg) than in L-NAME pretreated hypertensive rats 
(Emax > 60 mmHg). Thus, L-serine mediated reduction in MAP was more profound in L-
NAME pretreated hypertensive rats where NO production was compromised due to NOS 
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inhibition.  Thus, when the NO system is blunted, the EDHF mechanism is overactive to 
compensate endothelium-dependent vasodilatation (Desai et al., 2006; Bellien et al., 2006).  
 
5.2.1. NOS Inhibition Exaggerated L-serine Mediated Effect  
 EDHF mediated endothelium dependent vasodilatation is lower when NO system is 
active (Bauersachs et al., 1996; Busse et al., 2002).  Some earlier reports suggested that L-
serine modulates endothelium derived NO generation by increasing the efflux of L-arginine 
which serves as a precursor for NO (Kakoki et al., 2006).  L-serine mediated vasodilatation 
in isolated mesenteric arterioles was inhibited by pretreatment with apamin and TRAM-34 
combination in L-NAME pretreated hypertensive rats.  Similarly, the BP lowering effect of 
L-serine was also attenuated by pretreatments with apamin and ChTX combination.  L-
serine did not evoke a vasodilator response in arterioles isolated from L-NAME pretreated 
hypertensive rat pretreated with either a combination of ouabain and Ba2+ or depolarized 
with KCl.  These results suggest that L-serine increases K+ conductance in myendothelial 
junctions by activating SKCa and IKCa channels present on the endothelium and the increase 
in K+ conductance activates Na
+/K+ ATPase in the adjacent VSMC.  The subsequent efflux 
of K+ through Kir channels causes hyperpolariztion of the adjacent VSMC and contributes 
to the vasodilatation observed in resistant type mesenteric arterioles (Edwards et al., 1998). 
L-serine evoked profound fall in MAP in L-NAME pretreated hypertensive rats were not 
related to its elevated MAP since the fall in MAP in SHR was lower irrespective of its 
higher MAP compared to L-NAME pretreated hypertensive rats.  From in vitro and in vivo 
data, it is evident that acute L-serine infusion evoked a dose dependent vasodilatation and 
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fall in MAP which was higher in L-NAME pretreated hypertensive rats when NO path way 
is compromised.  Several candidates are suggested to play a role as mediator of EDHF in 
different vascular beds.  They are K+, EET, H2O2, CNP and MEGJ which are proposed to 
produce endothelium dependent vasodilatation.  Their responses were resistant to inhibitors 
of COX and NOS (Edwards et al., 1998; Busse et al., 2002; Chauhan et al., 2003; Feletou et 
al., 2006).  Although in NO compromised state EDHF plays a compensatory role and 
contributes to agonist mediated vasodilatation it does not appear to contribute to the 
maintenance of basal vascular tone (Desai et al., 2006; Parkington et al., 2002).  
 
5.3. BP Lowering Effects of L-serine Compared to its Stereoisomer D-serine 
 L-serine is converted to D-serine in vivo (de Koning et al., 2003 and 2004).  It is 
possible D-serine could contribute to the antihypertensive effect of L-serine.  To address 
this issue, we compared the fall in MAP evoked by L-serine and its stereoisomer, D-serine, 
in normotensive WKY, L-NAME pretreated hypertensive and SHR strains.  Data from the 
present study shows that acute infusion of D-serine also produced a reversible, dose 
dependent fall in MAP like L-serine without a significant increase in HR in all strains.  
However, the D-serine evoked fall in MAP was much lower compared to L-serine in all 
these rat models.  This data is consistent with our in vitro data that L-serine evoked 
vasodilatation and BP lowering effect is more pronounced in NO compromised state.  BP 
lowering effect of D-and L-serine was significantly inhibited by pretreatment with a 
combination of SKCa and IKCa channel inhibitors (apamin and ChTX) both in L-NAME 
pretreated hypertensive WKY and SHR strains.  The degree of inhibition observed with L-
 121
serine was higher compared to D-serine in SHR rats (Figure 11 b).  These results are 
similar and consistent with the results obtained using age matched L-NAME pretreated 
hypertensive Sprague-Dalwey rats.  
 
5.4. Comparison of L-serine and Glycine Effect in Blood Pressure Regulation 
 To maintain intracellular concentration of one carbon groups in different cellular 
compartments, reversible interconversion between of L-serine to glycine and glycine to L-
serine occurs in eukaryotes (Appling et al., 1991).  Studies have shown that glycine 
decreases blood pressure, fatty acids and rectifies vascular dysfunction by reducing 
oxidative stress (Matilla et al., 2002; Brawley et al., 2003; Hafidi et al., 2004).  Therefore, it 
was important to examine and compare the responses to glycine along with D-and L-serine 
in the same rat models.  In normotensive WKY rats, comparable doses of acute glycine 
infusion elicited a dose dependent fall in MAP.  However, the degree of fall was 
comparable to D-serine but lower than L-serine.  In L-NAME pretreated hypertensive 
WKY rats and SHR strains acute glycine infusion dose dependently elevated the MAP and 
the degree of elevation was higher in L-NAME pretreated hypertensive WKY rats 
compared to SHR strains.  In the same L-NAME pretreated hypertensive WKY and SHR 
strains, L-serine evoked a dose dependent fall in MAP.  Pretreatment with selective NMDA 
receptor antagonist, MK-801, significantly inhibited the glycine evoked fall in MAP in 
normotensive rats and elevated MAP in hypertensive rats.  It failed to affect the 
hypotensive responses to L-serine.  Either the elevation or the fall in MAP evoked by 
glycine was absent in WKY rats subjected to acute L-NAME infusion.  These data suggest 
that glycine evokes a pressor response in rats that are hypertensive subsequent to either 
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chronic L-NAME treatment or in genetic model of SHR with prolonged phase of 
hypertension but not following the rapid elevation in MAP attained after acute infusion of 
L-NAME.  
 
5.4.1. Glycine but not L-serine Elevates MAP in Hypertensive Rat Models 
 Glycine is proposed to mediate NO-dependent vasodilatation via activation of 
NMDA receptors.  NMDA receptor activation promotes Ca2+ influx that results in increased 
NOS activity.  This has been demonstrated in kidney and brain (Deng et al., 2002; Leung et 
al., 2002).  NMDA receptor antagonist or NOS inhibitor significantly inhibited the 
vasodilatation and increase in glomerular and tubular filtration evoked by glycine (Deng et 
al., 2002; Slamowitz et al., 2004; Qui et al., 1995; De Nicola et al., 1992).  Some studies 
have also reported that glycine mediated reduction in BP may be due to hyperpolarization 
of endothelial cells via activation of chloride channels (Wheeler et al., 2000).  The dose-
dependent fall in MAP following acute glycine (0.3 to 3.0 mmol/kg) infusion seen in the 
present study in normotensive WKY rats appears to be mediated by NO dependent NMDA 
receptor activation as reported earlier (Deng et al., 2002).  This depressor response was 
blocked by pretreatment with either the NMDA receptor antagonist, MK-801, or NOS 
inhibitor L-NAME.  Infusion of glycine in the same dose range as L-serine evoked a rapid 
reversible increase in MAP which was higher in L-NAME treated hypertensive WKY rats 
compared to SHR.  Despite progressive endothelial dysfunction in SHR, NO mediated 
response is not inhibited completely whereas in chronic L-NAME treated hypertensive rats, 
NO mediated responses are completely inhibited.  Thus, glycine mediated elevation in 
MAP was lower in SHR compared to L-NAME treated hypertensive rats.  Pretreatment 
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with NMDA receptor antagonist, MK-801, abolished the pressor response seen in both L-
NAME treated hypertensive and SHR models.  The present study shows that glycine 
evoked a depressor response in normotensive and pressor response in hypertensive rat 
models.  Both depressor and pressor response were sensitive to blockade by NMDA 
receptor antagonist, MK-801, or the NOS inhibitor L-NAME.  It has been reported that 
glycine mediated contractile response in isolated rat pial arteriole was sensitive to NMDA 
receptor antagonist (Huang et al., 1994).  In contrast to glycine, L-serine produced a dose 
dependent fall in MAP both in normotensive and hypertensive rat models.  This depressor 
response to L-serine was higher and more profound in hypertensive rat models whereas 
glycine elicited pressor response, which was opposite to L-serine evoked depressor 
response.  L-serine evoked profound fall in MAP was not sensitive to either NMDA 
receptor antagonist, MK-801, or NOS inhibitor L-NAME.  Thus, these data confirm that 
glycine and L-serine regulate BP differently by different mechanisms in normotensive and 
hypertensive rat models.  
 
5.5. Effect of L-threonine in Blood Pressure Regulation 
 L-threonine serves as a precursor to L-serine and it also promotes the subsequent 
formation of   D-serine, glycine and other metabolites of L-serine.  SHMT and L-threonine 
aldolase plays a role in the biosynthesis of L-serine in vivo.  Studies show that dietary 
administration of L-threonine in rat models over a period of six weeks elevates systolic BP 
via an increase in acetaldehyde formation (Vasdev et al., 1995).  In the present study 
comparable doses of acute L-threonine infusion did not affect either MAP or HR in all the 
rat models.  Based on these data, it is reasonable to conclude that L-serine mediated BP 
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lowering effect is profound in hypertensive rat models.  Compared to D-serine, L-serine is 
more potent and efficacious.  Acute L-threonine infusion has no effect on MAP or HR of 
any group of rat models.  Therefore, L-serine mediated response is unique, stereo-selective, 
not mimicked or shared by its precursor L-threonine, metabolites, D-serine and glycine.  
 
5.6. Comparison of Antihypertensive Effect of L-serine in Hypertensive Rat Models 
 In the present study, L-serine (0.1 to 3.0 mmol/kg) infusion evoked a dose 
dependent hypotensive response in normotensive and two well established hypertensive rat 
models.  The hypotensive response elicited by L-serine was higher and more pronounced in 
hypertensive rat models where NO pathway was compromised.  The dose of L-serine used 
in these studies was higher than the physiological plasma L-serine concentration which is 
130 ± 30 μmol (de Koning et al., 2004).  L-serine evoked profound fall in MAP was more 
pronounced in L-NAME pretreated hypertensive rats (≥ 93 mmHg) compared to SHR (≥ 80 
mmHg).  L-serine evoked fall in MAP was associated with a marginal increase in HR that 
did not attain statistical significance.  The higher initial baseline MAP in hypertensive rats 
was unrelated to the fall in MAP evoked by L-serine compared to normotensive control 
rats, since in SHR strains L-serine (3.0 mmol/kg) evoked fall in MAP was lower compared 
to L-NAME pretreated hypertensive rat model despite higher initial baseline MAP.  
 
5.7. Regional and Systemic Hemodynamic Assessment to L-serine  
 L-serine infusion evoked significant changes in CO, CI, MAP, TPR and TPRI by 
increasing regional blood flow to various tissues, which was greater in hypertensive rats.  
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5.7.1. L-serine Targets Multiple Vascular Beds in Hypertensive Rats  
 Acute L-serine infusion evoked a rapid fall in MAP in normotensive WKY (24 
mmHg), L-NAME treated WKY (65 mmHg) and SHR (57 mmHg) strains.  Changes in HR 
attained were not statistically significant although the increase in HR was noticed in both 
normotensive as well as hypertensive rat models (Table 8).  L-serine infusion led to a 
significant increase in blood flow to several organs that includes small intestine, spleen, 
diaphragm, skeletal muscle, large intestine, liver, kidney, heart and pancreas.  L-serine 
evoked changes in blood flow to brain, lungs and stomach in both SHR and L-NAME 
treated rats were minimal or negligible.  In contrast, in normotensive rats, L-serine induced 
increase in blood flow was significant only in small intestine (Table 5).  The degree of 
increase in blood flow to several organs was significantly different between L-NAME 
treated hypertensive WKY and SHR.  L-serine induced blood flow was higher in organs of 
hypertensive rat models compared to normotensive rats.  The most common organ targeted 
by L-serine in all animal models was small intestine.  The increase in blood flow occurred 
in the following rank order amongst the strains studied: small intestine of WKY (74%, p < 
0.05), L-NAME treated hypertensive rat (392%, p < 0.001), SHR (265%, p < 0.01). 
Peripheral organ vascular resistance was higher in both hypertensive rat models (Table 7). 
Data collected from several experiments revealed that like regional blood flow, L-serine 
mediated decrease in organ vascular resistance in several organs were significantly 
different between L-NAME treated hypertensive WKY and SHR strains.  In normotensive 
WKY rats, L-serine mediated decrease in vascular resistance was observed only in small 
intestine (42%, p < 0.05) which was lower compared to L-NAME pretreated hypertensive 
WKY (79%, p < 0.001) and SHR strains (67%, p < 0.01).  L-serine infusion significantly 
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reduced the elevated vascular resistance in several tissues, small intestine, spleen, liver, 
large intestine, diaphragm, skeletal muscle and heart in L-NAME treated hypertensive 
WKY rat models.  There were no significant reduction in vascular resistance in stomach, 
brain, lungs, kidney and pancreas.  In SHR, acute L-serine infusion reduced vascular 
resistance in most organ studied but the degree of overall reduction in organ vascular 
resistance was lower in SHR than in L-NAME treated hypertensive rats.  The present data 
suggests that that L-serine induced increase in blood flow and decrease in organ vascular 
resistance occurred in several organs and this contributes to the profound fall in MAP in 
hypertensive rats.  L-serine mediated reduction in organ vascular resistance and increase in 
organ blood flow plays a critical role for its contribution to the systemic hemodynamic 
changes encountered in normotensive and hypertensive rat models.  In L-NAME treated 
hypertensive rats and the SHR, the reduction in organ vascular resistance was more 
pronounced compared to normotensive rats.  In hypertensive rat models basal MAP, TPR 
and TPRI were higher with reduced CO and CI (Table 8).  L-serine infusion significantly 
reduces MAP, TPR and TPRI in both hypersensitive models with significant increase in 
CO and CI.  This effect was more pronounced in L-NAME pretreated hypertensive WKY 
rats compared to SHR.  L-serine infusion induced a fall in MAP, TPR and an increase in 
CO in all strains.  However, the magnitude of fall in TPR, MAP and increase in CO 
encountered were significantly higher in the hypertensive rat models.  Over all, the results 
are consistent with the suggestion that L-serine induced changes in hemodynamic effects 
are dramatic in NO compromised state.  In both hypertensive rat models, L-serine induced 
profound fall in MAP.  It is due to decrease in peripheral organ vascular resistance and 
increase in peripheral organ blood flow in multiple tissues.  However, this effect is 
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predominant in splanchnic vascular beds.  Thus, the profound fall in MAP is due to 
increased blood flow promoted by L-serine in the intestinal and abdominal region of 
hypertensive rat.  Blood flow to the visceral organs is maintained by splanchnic vascular 
network which accounts for one fourth of the total CO (Isabelle et al., 2008; Rowell, 1973; 
Perko et al., 1998).  L-serine induced increase in organ blood flow is sensitive to 
pretreatment with apamin and charybdtoxin in several tissues that includes heart, spleen, 
small intestine, diaphragm, and skeletal muscle in L-NAME treated hypertensive rats 
compared to recruitment of vascular beds of spleen, lungs, diaphragm, small and large 
intestine in SHR strain (Figure 28, 29, 30, 31 and 32).    
 
5.8. Proposed Mechanisms for L-serine Mediated Vasodilatation 
 L-serine mediated vasodilatation is endothelium dependent and NO as well as COX 
independent.  This response is sensitive to combined treatment with apamin and ChTX.  
This result suggests that L-serine promotes K+ efflux by activating SKCa and IKCa channels 
present in the endothelium.  The efflux of K+ from endothelium hyperpolarizes the VSMC 
via activation of the Na+ pump and subsequent efflux of K+ through Kir channels.  L-serine 
could activate SKCa and IKCa channels present in endothelium in one of the following ways: 
1) L-serine could activate its own receptor which may be present in the endothelium 
leading to an increase in Ca2+, which then activate SKCa and IKCa channels.  2)  L-serine 
can enter directly in to the endothelial cell via L-type amino acid transporter (LAT) and 
then activate SKCa and IKCa channels directly or it can activate EDHF directly which in turn 
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hyperpolarizes VSMC by decreasing resting membrane potential (RMP).  A schematic 
representation of L-serine mediated vasodilatation is proposed as follows (Figure 33). 
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Figure 33. Possible pathways of L-serine mediated vasodilatation.  
BK, bradykinin; ACh, acetylcholine; COX, cyclo-oxygenase; LAT, L-amino acid 
transporter; PGI2, prostacyclin; eNOS, endothelial nitric oxide synthase; NO, nitric oxide; 
EDHF, Endothelial hyperpolarizing factor; IKCa, calcium activated intermediate 
conductance potassium channel; SKCa, calcium activated small conductance potassium 
channel; K+, potassium; Na+, sodium; [Ca2+]i, intracellular calcium; AC, adenylyl cyclase; 
GC, guanylyl cyclase; cAMP, cyclic 3’, 5’ adenosine monophosphate; cGMP, cyclic 3’, 5’ 
guanosine monophosphate; RMP, resting membrane potential. 
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CHAPTER 6. CONCLUSIONS AND FUTURE WORK 
 
6.1. Summary of Major Findings 
 The in vitro studies revealed that L-serine evokes concentration-dependent (10 to 
200 µmol/L) vasodilatation in phenylephrine constricted endothelium-intact, but not in 
endothelium-denuded vessels.  The vasodilator response to L-serine is unaffected by the 
inclusion of NOS inhibitor, L-NAME and COX inhibitor, indomethacin, but is abolished by 
the inclusion of a combination of apamin (SKCa channel inhibitor) and TRAM-34 (IKCa 
channel inhibitor) or ouabain (Na+ pump inhibitor) and Ba2+ (Kir channel inhibitor) when 
the vessels were constricted by KCl.  The maximal response to L-serine was higher in the 
L-NAME treatment group (L-NAME 40% vs. control 20%) in contrast to the Emax to ACh 
(L-NAME 79% vs. control 93%).   
 
The data from the in vivo studies are consistent with our in vitro observations.  L-serine 
evokes a rapid, reversible, dose-dependent fall in MAP, which is more pronounced in L-
NAME treated rats (>60 mmHg) than the control rats (25 mmHg).  This was inhibited by 
apamin plus charybdotoxin pretreatment.  D-serine evokes less vasodilatation than L-serine 
in normotensive rats as well as in L-NAME induced hypertensive rats, and in the SHR 
strain.  While comparable doses of glycine also evoke a fall in MAP in normotensive rats, 
unlike L-serine, glycine increases MAP in both models of hypertension.  The most 
profound elevation of MAP was observed in the L-NAME pretreated hypertensive rats.  
Both the hypotensive and hypertensive responses to glycine are blocked by pretreatment 
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with the NMDA receptor antagonist, MK-801.  However, the responses to L-serine was not 
affected by MK-801.  Thus, the BP changes evoked by glycine and L-serine are unrelated 
and work through different mechanisms.  L-threonine, a precursor of L-serine, did not 
affect the MAP or HR in hypertensive rats.  Based on these findings, it is reasonable to 
conclude that the antihypertensive effect of L-serine is not shared or mimicked by its 
isomer, metabolite or its precursor.  
 
L-serine infusion promotes significant increase in blood flow and decrease in vascular 
resistance in several organs of hypertensive rats.  This contributes to the profound BP 
lowering effect of acute L-serine infusion despite higher MAP and TPR observed in L-
NAME pretreated hypertensive and in SHR strains.  L-serine increases in blood flow 
predominantly in targets intestinal and splanchnic vascular beds, and this is higher in 
hypertensive rat models.  Acute L-serine infusion led to a significant reduction in TPR, 
followed by substantial increase in CO which accounts for the profound fall in MAP in L-
NAME pretreated hypertensive WKY and SHR strains.  Apamin and ChTX pretreatment 
inhibited L-serine induced increase in regional blood flow to several organs in hypertensive 
rats with the maximal effect seen in the splanchinc region and intestinal vascular beds.   
 
Taken together, the data from the present study suggest that the non-essential amino acid, 
L-serine, evokes endothelium-dependent, NO-independent, COX-independent, but apamin 
plus charybdotoxin sensitive, activation of endothelial SKCa and IKCa channels that lead to 
endothelium-dependent hyperpolarization of adjacent VSMC.  This results in vasodilatation 
of rat mesenteric arterioles.  The data from the regional hemodynamic studies confirmed 
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that this effect of L-serine is not wide spread but occurs mainly in the splanchnic region and 
more particularly in the small intestinal vascular beds.  Moreover, the vasodilator responses 
evoked by L-serine in different vascular beds are greater in the hypertensive rat models. 
However, increased blood flow was seen predominantly in the splanchnic vascular beds 
with reduced regional vascular resistance which in turn contributes to reduced TPR and the 
fall in MAP, an effect that is exaggerated in hypertensive rats.  
 
6.2. Significance and Clinical Perspective of the Work 
 L-serine evoked vasodilatation and BP lowering effect was more profound in the 
NO compromised state.  Progressive endothelial dysfunction and reduced NO 
bioavailability with increased TPR and MAP values are the major manifestation and 
reflection of the underlying cardiovascular disease in condition like essential hypertension, 
atherosclerosis and diabetes.  The present study shows that acute L-serine infusion has 
potential to reduce the elevated TPR and MAP with minimal increases in HR by increasing 
blood flow and decreasing vascular resistance in several organs of hypertensive rats.  Oral 
treatment with L-serine (600 to 1400 mg/kg/day) has been shown to be beneficial in the 
management of neurological disorders and chronic fatigue syndrome without any adverse 
effect (Addington, 1999; Klomp et al., 2000; de Koning et al., 2004).  A recent report 
suggested that oral supplementation of L-serine reduces high cholesterol induced fatty 
streak formation in hypercholesterolemic rabbits without affecting plasma lipid levels 
(Movahedian et al., 2006).  High level of plasma homocysteine is a risk factor for 
cardiovascular disease since it reacts with reactive oxygen intermediates by auto-oxidation 
that damages endothelial cells and contributes to thrombosis (van Guldener et al., 2001). 
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Another study shows that elevated level of homocysteine increases bone fracture (McLean 
et al., 2004).  Dietary supplementation of L-serine has homocysteine lowering effect in 
humans (Verhoef et al., 2004).  These reports suggested that L-serine has some indirect 
cardiovascular protective effects by lowering plasma homocysteine level and fatty streak 
formation.  The present study shows that L-serine has potential to reduce BP in 
hypertensive animals.  Supplementation of L-serine alone or in combination with other 
antihypertensive agents could be considered in the management of hypertension.  L-serine 
infusion improves blood flow and decreases vascular resistance in multiple organs.  Most 
markedly in the splanchnic vascular beds.  It has been shown that multiple organ failure 
occurs due to splanchnic ischemia, which reduces oxygen delivery to various tissues (Krack 
et al., 2005).  Inadequate perfusion destroys the gastrointestinal barrier causing acidosis, 
which helps in releasing enteric bacterial toxins to systemic circulation, which in turn 
increases mortality in intensive care patients (Riddington et al., 1996; O’ Dwyer et al., 
1997).  L-serine can be synthesized from glucose and other glycolytic intermediates (de 
Koning et al., 2003 and 2004).  Thus, increased glucose absorption and its metabolism 
could elevate L-serine level in plasma, which in turn could enhance intestinal and 
splanchnic blood flow.  Increase in perfusion to the splanchnic region provides adequate 
oxygen supply to various tissues and contributes to the absorption of nutrients.  Thus, L-
serine mediated increased blood flow in these vascular beds could play an important role 
not only in the absorption of nutrients but also help in the regulation of MAP and promote 
beneficial cardiovascular protective effect.  A number of reports suggest the importance of 
postprandial elevation in blood flow in the intestinal and splanchnic region (Takagi et al., 
1988; Eriksen et al., 1994).  Therefore, L-serine could be evaluated for its therapeutic 
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benefit in overcoming conditions associated with reduced splanchnic perfusion in the 
future. 
 
6.3. Limitations of the Study and Possible Avenues for Future Directions 
 i) Our in vitro studies show that L-serine evokes endothelium-dependent 
vasodilatation via activation of KCa channels on the endothelium and evokes 
hyperpolarization of the adjacent VSMC.  It is unclear whether the L-serine effect is 
mediated via its putative cell surface receptor present on the EC or it occurs subsequent to 
L-serine movement through the neutral amino acid transporter, at the large neutral amino 
acid transporter, which is likely linked to activation of SKCa and IKCa channels present on 
the EC.  Thus, cellular studies towards characterization of the signaling mechanism that 
would link L-serine in opening endothelial KCa channels are warranted.   
 
ii) The present study suggests that L-serine, like ACh, bradykinin and ghrelins, promotes 
endothelium-dependent hyperpolarization (Edwards et al., 1998; Busse et al., 2002; Feletou 
and Vanhoutte, 2006; Moazed et al., 2009).  While the pharmacological evidence strongly 
supports a role for L-serine in activating the endothelium-dependent hyperpolarization, 
direct membrane potential recordings have not been conducted to establish this 
phenomenon.  This remains to be addressed. 
  
iii) Both L-serine and glycine are often included in cell culture medium as an essential 
nutrient and the possible effects of L-serine on cell growth and cell survival in EC and 
VSMC in primary culture is worthy of consideration.  
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iv) The responses to L-serine have been performed following its acute i.v. infusion in bolus 
doses and it is unclear whether it would be feasible to demonstrate a similar effect of L-
serine subsequent to oral administration of high doses.  The possibility exists that L-serine, 
could remain ionized in the gastrointestinal tract and not be absorbed.  This may pose 
problems concerning its oral bioavailability.  This too needs to be examined.    
 
v) The present study was conducted in anaesthetized rat models.  It is important to track the 
changes in MAP and HR for a longer period following chronic administration of L-serine in 
conscious, freely moving rats using radiotelemetry recording. 
 
vi) The study was remains focused on the examination of L-serine and glycine induced 
changes in MAP and HR in normotensive, in L-NAME treated hypertensive rats and in the 
SHR model.  It is known that endothelin antagonists such as bosentan are not effective as 
antihypertensive agents in the SHR model, but do lower the BP of salt-sensitive DOCA-salt 
model of hypertension (Schiffrin, 1998; Yu, Gopalakrishnan and McNeill, 1999).  Thus, the 
effects of L-serine on hemodynamic parameters should be examined in other animal models 
of hypertension and in diabetes.  
 
vii) The present study confirms that glycine infusion enhances pressor responses and thus 
differs from L-serine.  Glycine recruits NMDA receptors, and the pathways and 
mechanisms recruited by L-serine are different. Thus, examination of regional 
hemodynamic studies with glycine to investigate the vascular beds that contribute to 
vasoconstriction in hypertensive rat models assumes relevance.   
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viii) The L-serine evoked decrease in MAP is higher in L-NAME treated rats.  This 
confirms that the antihypertensive effect of L-serine is greater under conditions of reduced 
NO bioavailability.  It is important that the effects of L-serine infusion be compared in 
eNOS knockout mice and wild type mice to characterize the NO-independent effects of L-
serine. 
 
ix) L-serine infusion could be examined in other animals such as pigs and dogs.  In this 
regard, my supervisor has started hemodynamic studies in newborn piglets in collaboration 
with another investigator.  A similar dose-dependent fall in MAP and vascular resistance in 
the mesenteric vascular bed has been observed.  L-serine works in piglets in the same dose 
ranges as employed in the present study.  
 
x) Finally, a phase 1 clinical trial has been approved by the Human Ethics Board at the 
University of Saskatchewan to study the effects of the infusion of L-serine in normal 
human volunteers in an effort to establish the effects of L-serine on systemic 
hemodynamics.  
 
The scope and future work steming from the current findings is indeed vast and wide-
ranging.  To summarize, the present work provides pivotal new information from in vitro, 
in vivo and regional hemodynamic studies.  Thus, the present study provides the impetus 
and rationale for future studies along the lines enumerated above.  This work lays the 
foundation and opens a new avenue in our understanding of the role of individual amino 
acids in the regulation of BP.  Foods that high in L-serine are soybeans, lentils, mature 
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seeds, almonds, chickpeas, egg and yolk.  L-serine has the potential to be a nutraceutical 
agent, perhaps as an adjunct, in the management of hypertension.  
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